

European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack

European Stroke Journal
2022, Vol. 7(3) 1–XLI
© European Stroke Organisation 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/23969873221100032
journals.sagepub.com/home/eso



Jesse Dawson¹, Yannick Béjot^{2,3}, Louisa M Christensen⁴,
Gian Marco De Marchis⁵, Martin Dichgans^{6,7}, Guri Hagberg^{8,9},
Mirjam R Heldner¹⁰, Haralampos Milionis¹¹, Linxin Li¹²,
Francesca Romana Pezzella¹³, Martin Taylor Rowan¹,
Cristina Tiu^{14,15} and Alastair Webb¹²

Abstract

Recurrent stroke affects 9% to 15% of people within 1 year. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations on pharmacological management of blood pressure (BP), diabetes mellitus, lipid levels and antiplatelet therapy for the prevention of recurrent stroke and other important outcomes in people with ischaemic stroke or transient ischaemic attack (TIA). It does not cover interventions for specific causes of stroke, including anticoagulation for cardioembolic stroke, which are addressed in other guidelines. This guideline was developed through ESO standard operating procedures and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology. The working group identified clinical questions, selected outcomes, performed systematic reviews, with meta-analyses where appropriate, and made evidence-based recommendations, with expert consensus statements where evidence was insufficient to support a recommendation. To reduce the long-term risk of recurrent stroke or other important outcomes after ischaemic stroke or TIA, we recommend: BP lowering treatment to a target of <130/80 mmHg, except in subgroups at increased risk of harm; HMGCoA-reductase inhibitors (statins) and targeting a low density lipoprotein level of <1.8 mmol/l (70 mg/dl); avoidance of dual antiplatelet therapy with aspirin and clopidogrel after the first 90 days; to not give direct oral anticoagulant drugs (DOACs) for embolic stroke of undetermined source and to consider pioglitazone in people with diabetes or insulin resistance, after careful consideration of potential risks. In addition to the evidence-based recommendations, all or the majority of working group members supported: out-of-office BP monitoring;

¹Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

²Dijon Stroke Registry, Department of Neurology, University Hospital of Dijon, Dijon, France

³Pathophysiology and Epidemiology of Cardio-Cerebrovascular disease (PEC2), University of Burgundy, Dijon, France

⁴Dept of Neurology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark

⁵Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland

⁶Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

⁷Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

⁸Oslo Stroke Unit, Department of Neurology, Oslo University Hospital, Ullevål, Norway

⁹Department of medical research, Bærum Hospital Vestre Viken Hospital Trust, Drammen, Norway

¹⁰Stroke Research Center Bern, Department of Neurology, University and University Hospital Bern, Bern, Switzerland

¹¹Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece

¹²Wolfson Centre for Prevention of Stroke and Dementia, Department of Clinical Neurosciences, University of Oxford, Oxford, UK

¹³Stroke Unit, Department of Neuroscience, San Camillo Forlanini Hospital, Rome, Italy

¹⁴Department of Clinical Neurosciences, University of Medicine and Pharmacy 'Carol Davila', Bucuresti, Romania

¹⁵Department of Neurology, University Hospital Bucharest, Bucharest, Romania

Corresponding author:

Jesse Dawson, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Queen Elizabeth University Hospital, Glasgow G12 9QQ, UK.

Email: jesse.dawson@glasgow.ac.uk

use of combination treatment for BP control; consideration of ezetimibe or PCSK9 inhibitors when lipid targets are not achieved; consideration of use of low-dose DOACs in addition to an antiplatelet in selected groups of people with coronary or peripheral artery disease and aiming for an HbA1c level of <53 mmol/mol (7%) in people with diabetes mellitus. These guidelines aim to standardise long-term pharmacological treatment to reduce the burden of recurrent stroke in Europe.

Keywords

Guideline, systematic review, stroke, hypertension, dyslipidaemia, diabetes, antiplatelet

The full version of this guideline appears online.

Date received: 30 March 2022; accepted: 25 April 2022

Introduction

Approximately 1.1 million people in Europe suffer a stroke each year.¹ The majority of these are ischaemic, with approximately half as many people again experiencing a transient ischaemic attack (TIA).² People with a history of ischaemic stroke or TIA are at an increased risk of recurrent stroke and cardiovascular events, including myocardial infarction. Following ischaemic stroke, the rate of any recurrent stroke has been reported to range between 9% and 15% after 1 year, dependent on stroke aetiology.³ The rate of recurrent stroke at 10 years is reported as being between 27% and 40%. People with large artery disease have a reported rate of acute coronary syndrome of 22% over 10 years. In a recently reported international cohort study, 6% of people with TIA suffered a stroke within 1-year and 12% suffered a stroke or TIA.⁴

Several advances have recently been made in pharmacological preventative strategies for first and recurrent stroke. These include new drug classes for antithrombotic and lipid lowering therapy and for treatment of diabetes mellitus. In addition, several studies have assessed treatment targets for cholesterol and blood pressure (BP) level and compared investigative strategies to detect modifiable causes such as atrial fibrillation. Most cases of stroke can be explained by known cerebrovascular risk factors, with over 80% of the population attributable risk being explained by hypertension, smoking, diet, diabetes, alcohol use, psychological factors, activity levels and cardiac causes.⁵ There is therefore extensive opportunity to prevent recurrent stroke in people with stroke and TIA through readily available treatments. However, this can be hard to achieve in practice with several studies reporting sub-optimal risk factor control.⁶

The European Stroke Organisation (ESO) prepared a European Stroke Action Plan in 2018 which set targets to reduce the number of strokes in Europe by 10%.⁷ Effective secondary prevention measures, that are implementable on a wide scale, are key to this aim. The aim of this guideline is to provide recommendations to physicians treating people with ischaemic stroke or TIA to help them reach decisions regarding antithrombotic, BP lowering and lipid lowering treatment and regarding blood glucose control for prevention of recurrent stroke. The use of short term dual antiplatelet therapy early after minor stroke and high-risk TIA,⁸ secondary prevention in people with atrial fibrillation⁹ or

haemorrhagic stroke¹⁰ and acute management after stroke or TIA¹¹ are covered in other guidelines. The use of lifestyle measures to prevent stroke will be discussed in future guidelines.

Methods

Composition and approval of the Module Working Group

These guidelines were initiated by the ESO. Two chairpersons (JD and AW) were selected to assemble and coordinate the Guideline Module Working Group (MWG). The final group contained 13 experts. The ESO Guideline Board and Executive Committee reviewed the intellectual and financial disclosures of all MWG members and approved the composition of the group. The full details of all MWG members and their disclosures is included in Supplemental Materials.

Development and approval of clinical questions

The guidelines were developed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology¹² and the ESO Standard Operating Procedure (SOP),¹³ as described previously. In brief, the MWG developed a list of topics, and corresponding outcomes of clinical interest, within four key topic areas: (1) BP management; (2) lipid-lowering therapy; (3) antithrombotic therapy and (4) management of diabetes mellitus. The topics and outcomes were independently rated by each group member as critical, important or of limited importance according to GRADE criteria. The list of outcomes and results of voting are given in Table 1. Critical outcomes were defined as having either a mean or median score of 7 or more. Once critical outcomes had been identified, we established whether they were critical for all four key topic areas. Any stroke, ischaemic stroke and major cardiovascular events were viewed as critical for all four topic areas. Bleeding outcomes were agreed as critical for lipid lowering and antithrombotic population, intervention, comparator, outcome (PICO) questions. To avoid duplication, we included haemorrhagic stroke as a critical outcome but not intracranial bleeding. Functional outcome was initially rated as critical, but it was agreed that this would be downgraded to important and not be used to influence summary GRADE certainty assessment as there

would be little data on this outcome in secondary prevention trials. Dementia was rated as important and was included as an outcome for the PICO questions as we agreed readers would be interested in this outcome if data were available. However, it was not used to influence summary of GRADE certainty. In addition, we defined in advance that the outcome for PICO question 2 was blood pressure level. For our overall assessment of quality of evidence for each PICO question we used the lowest level of evidence for a critical outcome unless otherwise stated.

A series of PICO questions were then developed and approved by the ESO Guideline Board and the ESO Executive Committee.

Literature search

Search terms were developed by the MWG and guideline methodologist. Where a validated search strategy was available, this was used or adapted. A single broad search was performed for each topic area. Identified titles were then reviewed separately for each PICO question. Where there was a recent relevant systematic review on the question of interest, the corresponding search strategy and results were used and updated as necessary. Search strategies are described in the Supplemental Materials. MTR, JD and AW agreed on the search terms for each PICO question.

The search was performed by the ESO Guideline methodologist (MTR). The following databases were searched: the Cochrane Library, Embase and Medline from inception to 9th April 2021. Search results were run through the Cochrane machine learning randomised controlled trial classifier, to restrict results to randomised controlled trials only.¹⁴ Reference lists of review articles, the authors' personal reference libraries, and previous guidelines were also searched for additional relevant records.

Search results were loaded into the web-based Covidence platform (Health Innovation, Melbourne, Australia) for assessment by the MWG. Two or more MWG members were assigned to independently screen the titles and abstracts of publications registered in Covidence and then assess the full text of studies determined to be potentially relevant. All disagreements were resolved by discussion between the two reviewers or by a third MWG member.

We excluded publications with only conference abstracts available. For a study to be considered eligible, all of the following criteria needed to be met: report of data from a randomised controlled trial; performed only in adults (≥ 18 years) with ischaemic stroke or TIA (or reported outcomes separately for this group); inclusion of at least 50 participants per treatment group; at least 3 months follow up; and assessment of an intervention specified by one of the included PICO questions. As PICO 2 assessed the efficacy of outpatient blood pressure monitoring, it included studies with a primary outcome of blood pressure control at 3 months or more.

Data analysis

Data extraction and analysis was performed by the ESO methodologist. In the case that relevant data were not reported in an eligible study, the corresponding author was contacted. In the case of no response, the co-authors of the study were also contacted. If no answer was received, data were considered as missing.

Where appropriate, fixed or random-effects meta-analyses were conducted using Review Manager (RevMan) software (Cochrane). Results were presented as estimates of effect with associated 95% confidence interval (95% CIs). Statistical heterogeneity across studies was assessed using the I^2 statistic, and classified as moderate ($\geq 30\%$), substantial ($\geq 50\%$) and considerable ($\geq 75\%$).¹⁵

Evaluation of the quality of evidence and formulation of recommendations

The risk of bias of each included randomised trial was assessed with the Cochrane Rob2 tool.¹⁶ As recommended, the evidence synthesis did not use a quality 'score' threshold but classified overall risk of bias at study level and then in aggregate.¹⁷

The results of data analysis were imported into the GRADEpro Guideline Development Tool (McMaster University, 2015; developed by Evidence Prime, Inc.) For each PICO question, and each outcome, the following were considered: risk of bias based on the type of available evidence (randomised or observational studies); inconsistency of results; indirectness of evidence, imprecision of results and other possible bias. GRADE evidence profiles/summary of findings tables were generated and used to prepare recommendations. 'Evidence-based Recommendations' were based on the GRADE methodology. The direction, strength and formulation of the recommendations were determined according to the GRADE evidence profiles and the ESO-SOP.^{12,13,18}

Finally, Expert Consensus Statements were added whenever the MWG considered that there was insufficient evidence available to provide Evidence-based Recommendations and where practical guidance is needed for routine clinical practice. The Expert Consensus Statements were based on voting by all expert MWG members. Importantly, these Expert Consensus Statements should not be regarded as Evidence-based Recommendations, since they only reflect the opinion of the writing group.

Drafting of the document, revision and approval

Each PICO question was addressed in distinct sections, in line with the updated ESO SOP.¹³ First, 'Analysis of current evidence' summarised current pathophysiological considerations followed by a summary and discussion of the results of the identified RCTs and other studies. Second, 'Additional information' was added when more details on the studies referred to in the first section were needed to provide information on

Table 1. List of outcomes included and results of voting.

Outcome	MWG 1	MWG 2	MWG 3	MWG 4	MWG 5	MWG 6	MWG 7	MWG 8	MWG 9	Mean score	Median score
Ischaemic stroke	9	9	9	9	9	9	9	8	9	8.89	9
Any stroke	9	9	9	9	9	9	9	9	9	9.00	9
Functional outcome	6	9	6	9	8	9	9	8	9	8.11	9
Haemorrhagic stroke	9	9	9	9	7	9	9	8	9	8.67	9
Myocardial infarction	6	9	9	9	4	8	9	7	9	7.78	9
Major cardiovascular events	7	9	9	9	6	8	9	7	9	8.11	9
Death	8	9	9	9	8	8	8	9	9	8.56	9
Cardiovascular death	8	9	9	9	9	9	9	8	9	8.78	9
Intracranial bleeding	7	9	9	6	7	9	9	8	9	8.11	9
Any major bleeding episode	7	7	8	4	7	6	6	9	7	6.78	7
Quality of life	6	5	6	6	6	6	7	6	5	5.89	6
Mild cognitive impairment	5	4	6	5	4	7	6	6	4	5.22	5
Dementia	6	6	6	5	6	8	7	6	6	6.22	6
White matter hyperintensity	3	4	4	5	3	5	5	3	3	3.89	4
Microbleeds	3	4	4	5	3	6	6	4	3	4.22	4
Brain atrophy	3	3	4	5	3	5	5	4	3	3.89	4
Extra-cranial bleeding	7	6	7	4	6	6	6	8	6	6.22	6
Renal failure	5	4	6	4	4	4	4	7	4	4.67	4
Fracture	5	2	3	3	5	2	2	5	2	3.22	3
Falls	5	2	4	3	4	2	3	5	2	3.33	3
Hypoglycaemia	5	3	5	3	5	2	3	5	4	3.89	4

Outcomes shown in bold were rated as critical on round 1 of voting.

key subgroup analyses of the included studies, on ongoing or future RCTs and on other studies which can provide important clinical guidance on the topic.

Third, an 'Expert Consensus Statement' paragraph was added whenever the MWG considered that insufficient evidence was available to provide evidence-based recommendations for situations in which practical guidance is needed for everyday clinical practice.

The Guideline document was reviewed several times by all MWG members and modified using a Delphi approach until consensus was reached. The final submitted document was peer-reviewed by two external reviewers, two members of the ESO Guideline Board and one member of the Executive Committee.

Results

Blood pressure lowering

PICO question 1: In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of any recurrent stroke?

Analysis of current evidence

Hypertension is a key risk factor for stroke. BP level has a log-linear relationship with risk of stroke. A 20 mmHg

systolic or 10 mmHg diastolic increase in BP is associated with an approximate doubling of the risk of stroke.¹⁹ Elevated BP after ischaemic stroke or TIA is also a risk factor for recurrence.^{19,20}

Our systematic review and search of associated reference lists identified 5482 titles, of which 281 were reviewed in full. Ten trials of antihypertensive drugs versus placebo after TIA or stroke were eligible,^{21–30} including reports of secondary prevention subgroups in larger trials of mixed populations. The shortest reported period from stroke to randomisation was a median of 15 days²³ with most trials enrolling people months after stroke.

Results for all considered outcomes and GRADE scoring are available in Table 2. On meta-analysis of data from nine trials,^{21–29} with a median duration of follow-up ranging from 2 to 4.5 years, there was a significant reduction in the odds of recurrent stroke by almost 20% (OR 0.81, 95% CI 0.71–0.92, $p=0.002$) with BP lowering treatment (Figure 1; Table 2). The use of BP lowering treatment would be expected to lead to 17 fewer strokes per 1000 people treated. There was substantial heterogeneity ($I^2=53$, $p=0.03$), giving only moderate certainty, largely due to the largest trial with one of the smallest achieved BP differences between groups (the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS)). An exploratory analysis removing PROFESS²³ resulted in a 25% reduction in stroke risk (OR 0.75, 95% CI 0.68–0.83) with no residual heterogeneity ($I^2=0$).

Table 2. GRADE evidence profile for PICO question 1: In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of recurrent stroke?

Certainty assessment			No. of participants			Effect		Certainty	Importance			
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Does blood pressure lowering treatment	No blood pressure lowering treatment	Relative (95% CI)	Absolute (95% CI)		
Any stroke												
9	Randomised trials	Not serious	Serious ^a	Not serious	Not serious	None	1631/19,107 (8.5%)	1905/19,215 (9.9%)	OR 0.81 (0.71–0.92)	17 fewer per 1000 (from 27 fewer to 7 fewer)	⊕⊕⊕○ Moderate	Critical
Ischaemic stroke												
3	Randomised trials	Not serious	Serious ^a	Not serious	Very serious ^b	None	1028/13,367 (7.7%)	1137/13,334 (8.5%)	OR 0.85 (0.68–1.05)	12 fewer per 1000 (from 25 fewer to 4 more)	⊕⊕⊕○ Moderate	Critical
Haemorrhagic stroke												
2	Randomised trials	Not serious	Serious ^a	Not serious	Very serious ^b	None	96/13,197 (0.7%)	143/13,240 (1.1%)	OR 0.66 (0.38–1.13)	4 fewer per 1000 (from 7 fewer to 1 more)	⊕○○○ Very low	Critical
Major cardiovascular events												
7	Randomised trials	Not serious	Serious ^a	Not serious	Not serious	None	2309/17,471 (13.2%)	2637/17,470 (15.1%)	OR 0.80 (0.69–0.94)	26 fewer per 1000 (from 42 fewer to 8 fewer)	⊕⊕⊕○ Moderate	Critical
Myocardial infarction												
6	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	299/17,374 (1.7%)	343/17,373 (2.0%)	OR 0.85 (0.69–1.04)	3 fewer per 1000 (from 6 fewer to 1 more)	⊕⊕○○ Low	Critical
Death												
7	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	1350/17,543 (7.7%)	1364/17,467 (7.8%)	OR 0.97 (0.90–1.05)	2 fewer per 1000 (from 7 fewer to 4 more)	⊕⊕○○ Low	Critical
Cardiovascular death												
6	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	589/17,374 (3.4%)	663/17,373 (3.8%)	OR 0.88 (0.78–0.99)	4 fewer per 1000 (from 8 fewer to 1 fewer)	⊕⊕⊕⊕ High	Critical
Dementia												
2	Randomised trials	Not serious	Not serious	Serious ^c	Very serious ^b	None	601/11,675 (5.1%)	626/11,700 (5.4%)	NA	NA	⊕○○○ Very low	Important
Functional outcome												
1	Randomised trials	Not serious	Not serious	Serious ^c	Very serious ^b	None	400/795 (50.3%)	405/838 (48.3%)	OR 1.08 (0.89–1.32)	20 more per 1000 (from 28 fewer to 68 more)	⊕○○○ Very low	Important

CI: confidence interval; OR: odds ratio; NA: not analysed (data for this outcome were not pooled).

^aSignificant heterogeneity according to I^2 statistic. However, heterogeneity significantly reduced following removal of one trial (PROFESS), justifying a 'Moderate Grading' for ischaemic stroke.^bFails to rule out harm (confidence intervals cross 1).^cRestricted population sample.




Figure 1. Forest plot for the risk of any stroke in randomised trials of antihypertensive medication versus placebo after stroke or TIA. Heterogeneity: $I^2=53$, $p=0.03$.




Figure 2. Forest plot for the risk of recurrent major adverse cardiovascular events in randomised trials of antihypertensive medication versus placebo after stroke or TIA. Heterogeneity: $I^2=72.506$; $Q=21.823$; $p=0.001$.

On meta-analysis of data from three trials^{22,23,30} there was a non-significant reduction in ischaemic stroke (OR 0.85, 95% CI 0.68–1.050, $p=0.13$). On meta-analysis of data from two trials^{22,23} there was a non-significant reduction in haemorrhagic stroke (OR 0.66, 0.38–1.13, $p=0.13$) but certainty was rated as very low due to a small number of events. There was a significant reduction in major cardiovascular

events (seven trials,^{22–28} OR 0.80, 95% CI 0.69–0.94, $p=0.006$, $I^2=72.5$, Figure 2, Table 2) and cardiovascular death (six trials,^{21,23–25,27,28} OR 0.88, 95% CI 0.78–0.99, $p=0.026$, $I^2=0$) with antihypertensive therapy (Table 2). There was no significant reduction in myocardial infarction (six trials,^{21,23–25,27,28} OR 0.85, 95% CI 0.69–1.04, $p=0.11$) and all cause death (seven trials,^{21,23–25,27,28} OR 0.97, 95% CI

0.90–1.05, $p=0.51$, $I^2=0$). There were insufficient data to allow analysis of the effect of antihypertensive medication on dementia and functional outcome and there were no significant differences seen for these outcomes in any individual trial we reviewed (Table 2).

There was no important concern of significant bias in the results, but there was substantial heterogeneity between studies for the outcomes of any stroke and major cardiovascular events. This led to a rating of only moderate certainty for these outcomes. However, as described above, this heterogeneity predominantly resulted from inclusion of PROFESS²³ which produced a more conservative estimate of the effect size. Exclusion of the PROFESS trial data from the analyses resulted in a greater difference between the intervention and control groups and removed our concerns regarding inconsistency. Therefore, taking this into account and because the level of certainty was high for cardiovascular death, we rated the overall quality of evidence as high for this PICO question. Achieved BP differences were variable between studies, ranging from 3.2/2.0 mmHg in PROFESS to 25.0/12.0 mmHg in HSCS.

Additional information

The conclusions of our meta-analyses are consistent with those of recent meta-analyses performed in 2018³¹ and 2017,³² based upon a very similar groups of trials. The latter of these analyses also supported a linear relationship between degree of BP reduction in these studies and achieved differences in outcomes. Furthermore, the effect of BP lowering in our meta-analysis is highly consistent with the benefits of BP lowering in primary prevention of stroke and other secondary prevention populations. In the largest available individual participant-level meta-analysis, there was an approximate 10% reduction in the risk of major adverse cardiovascular events for each 5 mmHg reduction in systolic BP in both primary and secondary prevention populations. In people with prior cardiovascular disease, there was a reduction in all major cardiovascular events by 11% (OR 0.89, 95% CI 0.86–0.92) and stroke by 11% (OR 0.89, 95% CI 0.85–0.94), but no effect for all cause death.³³

Benefits of BP reduction in individual participant-level meta-analyses in primary prevention were consistent regardless of baseline BP level, even down to normotensive levels (120/70 mmHg). However, confidence in benefits at these lower BP levels is limited due to heterogeneity between populations and smaller numbers.³³ The benefit of antihypertensive treatment in secondary prevention of stroke at mildly hypertensive levels is supported by the PROGRESS trial, in which the risk of recurrent stroke was reduced by treatment in both hypertensive and non-hypertensive populations, with hypertension defined as BP greater than 140/90 mmHg.

The timing of intervention in the studies included in our meta-analysis varied significantly, but treatment was not initiated in the acute phase in any of these trials, and the risk of

recurrent events was consistently reduced during follow-up. As such, our recommendations apply for all people after an ischaemic stroke or TIA, but do not provide a specific recommendation regarding the timing of initiation of therapy.

Evidence-based recommendation

In people with previous ischaemic stroke or TIA, we recommend blood pressure lowering treatment to reduce the risk of recurrent stroke.

Quality of evidence: **High** ⊕⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 2: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does use of out-of-office blood pressure measurements compared to clinic measurements provide better long-term control of blood pressure?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 5482 titles, of which 281 were reviewed in full. For this question we identified three trials comparing out-of-office BP measurements versus in office BP measurements in people after stroke or TIA.^{34–36}

The Trial of the Effectiveness of Self-monitoring/Treatment of BP after Stroke (TEST-BP) trial³⁶ randomised 171 participants with a recent stroke or TIA to self-BP monitoring with or without guided self-management of BP treatment versus treatment as usual. The primary outcome was difference in daytime ambulatory systolic BP (SBP) at 6 months. There were no significant mean between-group differences at 6 months (difference treatment as usual minus self monitoring and management, 2.69 mmHg (95% CI –2.59 to 7.97; $p=0.31$); treatment as usual minus self monitoring only, 3.00 mmHg (95% CI –2.53 to 8.54; $p=0.28$). Self-BP monitoring did not result in more participants achieving target BP, defined as daytime blood pressure on ambulatory monitoring of $\leq 120/75$ mmHg (treatment as usual 12/52 (23%), treatment as usual 8/51 (16%), self monitoring and management 13/51 (26%), $p>0.05$).

In the study by Kerry et al.³⁵ 381 participants with hypertension and a history of stroke or TIA were randomised to home BP monitoring or usual care. The primary outcome was a fall in systolic BP after 12 months. There was no significant mean between-group difference (0.3 mmHg, 95% CI –1.36 to 4.2). Subgroup analysis showed significant interaction with disability due to stroke ($p=0.03$ at 6 months) and baseline BP ($p=0.03$ at 12 months).

The Targets and Self-Management for the Control of Blood Pressure in Stroke and at Risk Groups (TASMIN-SR) Trial³⁴ randomised 552 participants with a history of stroke or TIA, coronary heart disease, diabetes chronic kidney disease and




Figure 3. Forest plot for the difference in achieved mean blood pressure between ‘treatment as usual’ and introduction of home or remote blood pressure monitoring after stroke or TIA. Heterogeneity: $I^2 = 0.000$; $Q = 1.509$; $p = 0.470$.




Figure 4. Forest plot for the reduction in the risk of recurrent stroke after TIA or minor stroke in participants randomised to an intensive blood pressure lowering strategy (<130/80) versus a less intensive strategy (<140/90). Heterogeneity: $I^2 = 0.000$; $Q = 1.509$; $p = 0.470$.

In adult people with ischaemic stroke or TIA there is continued uncertainty over the use of out-of-office blood pressure measurements.

selection seems essential to ensure the effectiveness of home monitoring. The panel voted by 12/12 members for the following consensus statement (Supplemental Table 2).

PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. blood pressure <130/80) versus less intensive (<140/90 mmHg) target reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 5482 titles, of which 281 were reviewed in full. For

this question we identified three trials in which an intensive BP reduction strategy was compared with a standard BP target and reported risk of recurrent stroke in people with a history of stroke or TIA.^{39–41} The Secondary Prevention of Small Subcortical Strokes (SPS3)³⁹ trial included 3020 participants with MRI-confirmed symptomatic lacunar ischaemic stroke within 180 days to compare a SBP target of 130 to 149 mmHg versus a SBP <130 mmHg. After a mean follow-up of 44 months, the primary endpoint (all strokes) was observed in 125 (2.25%) participants in the intensive SBP target group versus 152 (2.77%) participants in the standard SBP target group (HR 0.81, 95% CI 0.64–1.03, $p = 0.08$). The intensive SBP reduction strategy was associated with a reduction in haemorrhagic stroke (HR 0.37, 95% CI 0.15–0.85, $p = 0.03$). No statistically significant difference was observed between groups for other secondary outcomes including ischaemic stroke (HR 0.84, 95% CI 0.66–1.09, $p = 0.19$), myocardial infarction (HR 0.88, 95% CI 0.56–1.39, $p = 0.59$), major vascular events (HR 0.84, 95% CI 0.68–1.04, $p = 0.1$), all-cause

death (HR 1.03, 95% CI 0.79–1.35, $p=0.82$) and vascular death (HR 0.86, 95% CI 0.55–1.35, $p=0.52$). There was no significant difference in terms of serious adverse events. The Prevention After Stroke-Blood Pressure (PAST-BP) trial⁴⁰ enrolled 529 participants from 99 General Practices in England identified from the practice's TIA/stroke register. A total of 52% had suffered TIA and the remainder stroke. The type of stroke was not defined. Participants were randomised to intensive SBP reduction defined as SBP target <130 or a 10 mmHg reduction if baseline SBP was <140 mmHg versus standard SBP target (<140 mmHg). The primary outcome was change in SBP between baseline and 12 months. A recurrent stroke was observed in no participant in the intensive SBP target group versus 3 participants in the standard SBP target (RR 0.14, 95% CI 0.01–2.72). There was no difference between groups regarding major vascular events, myocardial infarction, total death vascular death, as well as adverse symptoms.

In the Recurrent Stroke Prevention Clinical Outcome Study (RESPECTS),⁴¹ 1280 participants with a history of stroke <3 years (of whom 85% had a history of ischaemic stroke and 15% had intracerebral haemorrhage) were randomised to intensive BP reduction (BP target $<120/80$ mmHg) versus standard BP reduction ($<140/90$ or $<130/80$ mmHg for people with diabetes, chronic kidney disease a history of myocardial infarction). The primary endpoint (any recurrent stroke) was observed in 39 (1.65%) participants in the intensive treatment group versus 52 (2.26%) in the standard treatment group after a mean follow-up of 3.9 years (HR 0.73, 95% CI 0.49–1.11). Intracerebral haemorrhage was less frequent in the intensive BP reduction group (HR 0.09, 95% CI 0.01–0.70), whereas no difference was observed for major vascular events, myocardial infarction all-cause death. Serious adverse events were similar between the two groups.

Additionally, our literature search found a single-blinded trial conducted in South Korea by Park et al.⁴² A total of 132 participants with a recent (7–42 days) ischaemic stroke related to intracranial atherosclerotic stenosis were randomly allocated to intensive (SBP 110–120 mmHg) or standard (SBP 130–140 mmHg) BP control groups. The primary endpoint was the white matter lesion volume change on MRI between baseline and 24 weeks. This did not differ between groups. At 24 weeks, a new ischaemic stroke event was reported in one participant in both the intensive and the standard BP reduction groups. There were no vascular deaths in the study and the frequency of adverse events did not differ between the two groups.

Results for all considered outcomes and GRADE scoring, is available in Table 4. On meta-analysis of data from three trials^{39–41} there was a significant reduction in recurrent stroke with intensive BP treatment compared with a standard BP reduction strategy (OR 0.79, 95% CI 0.64–0.98, $p=0.029$) (Figure 4). There was no evidence of heterogeneity and the level of certainty was rated as high. Use of an intensive blood pressure target would be expected to lead to 17 fewer cases of stroke per 1000 treated. There was a non-significant reduction in ischaemic stroke with inten-

sive BP treatment on meta-analysis of data from three trials^{39,41,42} (OR 0.87, 95% CI 0.69–1.09, $p=0.228$).

On meta-analysis of data from two trials,^{39,41} there was a significant reduction in haemorrhagic stroke with intensive BP reduction (OR 0.25, 95% CI 0.07–0.90, $p=0.033$, Table 4, Figure 5). There was no significant difference between groups for the outcomes of major vascular events, myocardial infarction, all-cause death vascular death on meta-analysis (Table 4). Finally, functional outcome was only assessed in the SPS3 trial.³⁹ There was no significant difference between intensive and standard BP reduction groups for poor outcome defined as a mRS score ≥ 3 (OR 0.82, 95% CI 0.54–1.25).

Additional information

There was some heterogeneity between trials in terms of participants enrolled; SPS3³⁹ only included people with lacunar stroke, PAST-BP⁴⁰ included people with TIA and stroke, RESPECTS⁴¹ included people with haemorrhagic stroke, and Park's trial focussed on people with ischaemic stroke related to intracranial atherosclerotic stenosis. Outcomes were not reported according to baseline characteristics meaning it is difficult to generalise recommendations for specific subgroups. Other studies suggest caution regarding intensive BP reduction for some groups of people. For instance, pooled data from the European Carotid Surgery Trial (ECST) and the North American Symptomatic Carotid Endarterectomy Trial (NASCET) showed that there was a relationship between higher stroke risk and lower blood pressure in people with bilateral severe ($\geq 70\%$) internal carotid artery stenosis.⁴³ In addition, the mean age of participants from the trials identified in our meta-analysis ranged between 63 and 72 years old, which is lower than that observed in population-based registries and in clinical practice.⁴⁴ This reflects the fact that elderly people were under-represented in randomised clinical trials, particularly those with frailty.⁴⁵ Indeed, in one study these participants had a greater risk of stroke with intensive treatment (adjusted HR 1.93; 95% CI 1.04–3.60, $p=0.038$), without a difference in wider cardiovascular outcomes or all-cause mortality, and an increased risk of hypotension and syncope.⁴⁵ Considering that pre-existing mild cognitive impairment is common in people with stroke,^{46,47} additional research is needed to clarify the best BP target in people with stroke and cognitive impairment. In general, BP reduction in older people (aged >80 years) can be expected to reduce risk of stroke as shown in a large study of indapamide with or without an ACE inhibitor.⁴⁸ Another issue is the impact of intensive versus usual BP control on kidney function. A sub-analysis of SPS3 demonstrated a greater likelihood of rapid kidney function decline with intensive BP reduction, although this was not associated with an increased risk of clinically important events.⁴⁹ This was also seen in the Systolic Blood Pressure Intervention Trial (SPRINT), where intensive BP reduction was associated with a reduction in estimated glomerular filtration rate, although this effect was outweighed by

Table 4. GRADE evidence profile for PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. BP<130/80) versus less intensive (<140/90 mmHg) target reduce the risk of recurrent stroke?

Certainty assessment			No. of participants		Effect		Certainty	Importance
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Relative (95% CI)	Absolute (95% CI)
<i>Any stroke</i>								
3	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	OR 0.79 (0.64–0.98)	17 fewer per 1000 (from 30 fewer to 2 fewer)
<i>Ischaemic stroke</i>								
3	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	OR 0.87 (0.69–1.09)	10 fewer per 1000 (from 23 fewer to 7 more)
<i>Haemorrhagic stroke</i>								
2	Randomised trials	Not serious	Not serious	Not serious	Serious ^b	None	OR 0.25 (0.07–0.90)	9 fewer per 1000 (from 12 fewer to 1 fewer)
<i>Major cardiovascular events</i>								
4	Randomised trials	Not serious	Not serious	Not serious	Serious ^a	None	OR 0.83 (0.68–1.00)	17 fewer per 1000 (from 31 fewer to 0 fewer)
<i>Myocardial infarction</i>								
3	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	OR 0.94 (0.62–1.44)	1 fewer per 1000 (from 7 fewer to 8 more)
<i>Death</i>								
3	Randomised trials	Not serious	Not serious	Not serious	Very serious ^c	None	OR 1.00 (0.78–1.28)	0 fewer per 1000 (from 12 fewer to 15 more)
<i>Cardiovascular death</i>								
3	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	RR 0.86 (0.58–1.27)	3 fewer per 1000 (from 9 fewer to 6 more)
<i>Functional outcome</i>								
1	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	OR 0.82 (0.54–1.26)	6 fewer per 1000 (from 15 fewer to 8 more)

CI: confidence interval; RR: risk ratio; OR: odds ratio.

^aFails to rule-out harm (confidence intervals cross over 1).^bFew events and moderate sample size (optimal information size (OIS) not met).^cFails to rule out benefit or harm (confidence intervals cross over 1). There were no data for dementia and major bleeding outcomes.




Figure 5. Forest plot for the reduction in the risk of recurrent haemorrhagic stroke after TIA or stroke in participants randomised to an intensive blood pressure lowering strategy (<130/80) versus a less intensive strategy (<140/90). Heterogeneity: $I^2 = 36.402$; $Q = 1.572$; $p = 0.210$.

cardiovascular and all-cause mortality benefits,⁵⁰ and the impact on longer-term kidney outcomes remains to be determined. As such, a more cautious approach to intensive blood pressure lowering may be warranted in people with bilateral, severe carotid stenosis, older age, cognitive impairment or pre-existing renal disease. Overall, we rated the quality of evidence as moderate, although it was high for the outcome of any stroke.

PICO question 4: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does initiation of two blood pressure lowering medications compared to monotherapy reduce the risk of recurrent stroke?

Analysis of current evidence

The systematic review identified no trials in which initiation of a combination of antihypertensive medications was directly compared to initiation of a single agent in the secondary prevention of stroke or TIA, and no trial in which a specific combination of blood pressure lowering medications was compared to another combination of blood pressure lowering medications.

The perindopril protection against recurrent stroke (PROGRESS) trial was the only trial identified that randomised participants to a defined combination treatment, but the treating physician had discretion to choose whether monotherapy or combination treatment was used.²¹ As such, the perindopril and indapamide versus perindopril alone comparison is not a randomised comparison. In addition, the combination treatment arm was slightly more hypertensive at baseline. Nonetheless, combination treatment was associated with a greater reduction in blood pressure compared to placebo (12.5/5.0 mmHg) than monotherapy treatment versus placebo (4.9/2.8 mmHg), as well as a proportionately greater relative reduction in the risk of recurrent stroke (43% vs 5%).

Supporting information to the expert consensus statement

We conclude that in people with previous ischaemic stroke or TIA, there are insufficient data to provide a recommendation for the PICO question. Given that blood pressure lowering appears to have consistent effects in the setting of primary and secondary prevention with regard to stroke, we used data from primary prevention studies to help us reach a consensus. Trials have explored the use of combined therapy versus monotherapy in people with essential hypertension and show that this leads to better control of BP.^{51,52} A large systematic review and meta-analysis shows that the extra blood pressure reduction from combining two drug classes is approximately five times greater than doubling the dose of one drug.⁵³ Large observational cohort studies have demonstrated that initiation of combination therapy is associated with improved blood pressure control^{53,54} and improved adherence^{55,56} compared with monotherapy and with minimal additional side-effects, associated with significant reductions in clinical events compared to placebo.⁵³ This evidence underpins the current European Society of Hypertension and European Society of Cardiology guidelines⁵⁷ which recommend initiation of antihypertensive treatment with combination treatment, except in people at increased risk of hypotension and those with mild hypertension and low cardiovascular risk (not applicable to our stroke population). In the absence of alternative specific evidence for secondary prevention in stroke, and supportive evidence for the potential benefit of combination treatment in PROGRESS,²¹ this European guidance is therefore applicable for most people with prior stroke. Where possible, combination treatment should be provided as a single tablet where possible, to improve adherence.⁵⁸

There is limited direct evidence to guide the choice of medications to use in a combination regimen. In primary prevention trials, calcium channel blockers (CCBs)

appear to be slightly more efficacious than other classes in prevention of stroke, at the cost of an increased risk of symptomatic heart failure.^{59,60} This effect may be due to a greater consistency of blood pressure control with CCBs and thiazide-like diuretics. In contrast, inhibitors of the renin angiotensin system (RAS) are particularly effective in prevention of coronary artery disease and renal dysfunction, and angiotensin receptor blockers (ARB) have an excellent side effect profile.⁶¹ RAS inhibition plus a CCB was superior to RAS inhibition plus a diuretic in the The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial,⁶² but this was not confirmed in further less well powered trials.^{63,64} Therefore, based on primary prevention guidelines, plus supportive evidence from drug classes used in trials such as PROGRESS, initiation of treatment with a combination of antihypertensive medication, usually containing either a thiazide-like diuretic (such as indapamide) or a CCB (such as amlodipine or felodipine), combined with a RAS inhibitor (ACE inhibitor or angiotensin 2 receptor blocker) is reasonable. If a third agent is needed, a CCB or thiazide can then be added if not already in use. Further studies are required to determine optimal combinations, especially in secondary prevention of stroke the potential benefit of three drug combinations, as is currently being tested after intracerebral haemorrhage in the Triple Therapy Prevention of Recurrent Intracerebral Disease Events (TRIDENT) trial (NCT02699645). The panel voted by 10/12 members for the following consensus statement (Supplemental Table 2).

Evidence-based recommendation

—
Quality of evidence: —
Strength of recommendation: —

Expert consensus statement

In people with ischaemic stroke or TIA, we support initiation of a combination of two blood pressure lowering drugs to reduce the risk of recurrent stroke, with consideration of monotherapy where there are potential risks of hypotension, such as in frail, elderly people and people with borderline hypertension

In adult people with ischaemic stroke or TIA there is continued uncertainty over the initiation of two blood pressure lowering medications compared to monotherapy.

Lipid lowering therapy

PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke?

Evidence-based recommendation

In people with previous ischaemic stroke or TIA, we suggest aiming for a blood pressure target of <130/80mmHg to reduce the risk of recurrent stroke.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Weak for intervention** ↑?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We found five trials^{65–69} which directly addressed this PICO question. These trials included a total of 10,169 participants.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial,⁶⁶ which was published in 2006, included 4731 participants who had had an ischaemic stroke or TIA within 1 to 6 months before study entry. Participants were randomised to receive either 80mg atorvastatin daily or placebo. The primary outcome was any nonfatal or fatal stroke. The mean age of participants was 63 years and the mean duration of follow up was 4.9 years. There was a significant reduction in the primary outcome with atorvastatin 80mg daily (adjusted HR 0.84, 95% CI 0.71–0.99).

The Heart Protection Study Collaborative (HPSC),⁶⁵ included 20,536 people aged between 40 and 80 years with non-fasting blood total cholesterol concentrations of at least 3.5mmol/l (135mg/dl). Of these, 3280 had a history of prior cerebrovascular disease and these outcomes were reported separately; 63% of these had a history of non-disabling non-haemorrhagic stroke, 46% a history of TIA, 10% had undergone carotid endarterectomy and 2% carotid angioplasty. People with a stroke within the previous 6 months were excluded. In the main trial, participants were randomised to 40mg simvastatin daily or placebo. The primary outcome was occurrence of any stroke. The mean age of participants was 65 years, the mean duration of follow up was 4.8 years and the mean interval since the most recent stroke or TIA was 4.3 years. There was a significant reduction in the primary outcome with simvastatin 40 daily (HR 0.75, 95% CI 0.66–0.85).

The Japan Statin Treatment Against Recurrent Stroke (J-STARS) trial, which was published in 2015,⁶⁷ included 1578 participants (although a sample size of 3000 was initially planned) aged 45 to 80 years with a history of non-cardioembolic ischaemic stroke within the preceding 1 month to 3 years. Participants were randomised to receive pravastatin 10mg daily or no HMGCoA reductase inhibitor therapy. The primary outcome was stroke (expressed as rate (%) per year). The mean age of participants was 66 years and the mean duration of follow up was 4.9 years. Stroke rate was similar between the two arms with an annual rate of 2.4% with pravastatin versus 2.5% in the comparison group (adjusted HR 0.95, 95% CI 0.71–1.28).

The Cholesterol and Recurrent Events (CARE) trial was a secondary prevention trial comparing pravastatin 40mg/day after myocardial infarction.⁶⁸ A total of 4159 participants




Figure 6. Forest plot for the risk of any stroke in trials comparing treatment with HMGCoA reductase inhibitors versus placebo after TIA or stroke. Heterogeneity: $I^2=0.000$; Q -value = 2.473.

aged between 21 and 75 years were enrolled after a mean of 10 months from the index event. The median follow-up period was 5 years. A total of 100 participants in the placebo group and 111 participants in the pravastatin group had a history of prior stroke/TIA. HMGCoA reductase inhibitor treatment in this subgroup of participants led to a 37% relative risk reduction in stroke or TIA (95% CI 23–68).⁶⁸

The LIPID (the Long-Term Intervention with Pravastatin in ischaemic Disease) trial randomised 9014 participants with a median age of 62 years and a history of myocardial infarction or unstable angina during the previous 3 to 36 months to receive pravastatin 40 mg/day or placebo.⁶⁹ Prespecified secondary end points included stroke from any cause. The mean duration of follow-up was 6.1 years. A total of 610 participants ($n=325$ in the intervention group) had a history of cerebrovascular disease. Pravastatin treatment in these participants was associated with a relative risk of stroke of 0.72 (95% CI 0.46–1.12).⁷⁰

Results for all considered outcomes and GRADE scoring is available in Table 5. On meta-analysis of data from five trials^{65–69} there was a significant reduction in the rate of any stroke in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR 0.89, 95% CI 0.78–0.99, $p=0.049$) with little heterogeneity among the trials ($I^2=0$, p for heterogeneity = 0.65, Figure 6). The level of certainty was rated as high. Data suggest that use of a HMGCoA reductase inhibitor would be expected to lead to 13 fewer cases of stroke per 1000 treated.

Results were also consistent when the analysis was confined to the two trials that recruited participants early after their index ischaemic stroke (Supplemental Figure 1).

On meta-analysis of data from two trials,^{65,71} there was a significant reduction in the rate of ischaemic stroke in people

treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR 0.79, 95% CI 0.67–0.92; equivalent to 20 fewer events per 1000, 95% CI from 30 fewer to 7 fewer) (Table 5). The level of certainty was rated as high.

On meta-analysis of data from three trials^{65–67} there was a significant increase in the rate of haemorrhagic stroke in people treated with HMGCoA reductase inhibitors compared to no lipid-lowering therapy (OR 1.55, 95% CI 1.09–2.21); equivalent to six more events per 1000 (from 1 more to 14 more) (Figure 7; Table 5). The level of certainty was rated as high.

On meta-analysis of data from two trials^{65,71} there was a significant reduction in the rate of any major cardiovascular event in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR 0.78, 95% CI 0.70–0.87); equivalent to 40 fewer per 1000 (from 55 fewer to 22 fewer) (Table 5). The level of certainty was rated as high.

Only one trial reported data on the rate of myocardial infarction.⁶⁷ This showed that there was no significant reduction in the rate of myocardial infarction in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (HR 0.55, 95% CI 0.16–1.89); four fewer per 1000 (from seven fewer to eight more). The level of certainty was rated as very low due to imprecision.

On meta-analysis of data from two trials^{67,71} there was no reduction in the rate of death in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR 1.03, 95% CI 0.87–1.24) (Table 5). There was also no significant reduction in cardiovascular death (OR 0.78, 95% CI 0.58–1.06). The level of certainty was rated as low. Only one trial reported data on the rate of dementia.⁶⁷ This showed that there was no significant

Table 5. GRADE evidence profile for PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke?

Certainty assessment			No. of participants				Effect		Certainty	Importance
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	HMGCoA reductase inhibitors	No lipid-lowering therapy	Relative (95% CI)	Absolute (95% CI)
Any stroke										
5	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	558/5081 (11.0%)	622/5088 (12.2%)	HR 0.89 (0.78–0.99)	13 fewer per 1000 (from 25 fewer to 0 fewer)
Ischaemic stroke										
2	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	318/4006 (7.9%)	396/4005 (9.9%)	OR 0.79 (0.67–0.92)	20 fewer per 1000 (from 30 fewer to 7 fewer)
Haemorrhagic stroke										
3	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	87/4799 (1.8%)	56/4790 (1.2%)	OR 1.55 (1.09–2.21)	6 more per 1000 (from 1 more to 14 more)
Major cardiovascular events										
2	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	740/4006 (18.5%)	895/4005 (22.3%)	OR 0.78 (0.70–0.87)	40 fewer per 1000 (from 55 fewer to 22 fewer)
Myocardial infarction										
1	Randomised trials	Very serious ^b	Not serious	Not serious	Very serious ^a	None	4/793 (0.5%)	7/785 (0.9%)	HR 0.55 (0.16–1.89)	4 fewer per 1000 (from 7 fewer to 8 more)
Death										
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^c	None	259/3158 (8.2%)	246/3151 (7.8%)	HR 1.03 (0.87–1.24)	3 more per 1000 (from 10 fewer to 17 more)
Cardiovascular death										
1	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	78/2365 (3.3%)	98/2366 (4.1%)	HR 0.78 (0.58–1.06)	9 fewer per 1000 (from 17 fewer to 2 more)
Dementia										
1	Randomised trials	Very serious ^b	Not serious	Not serious	Very serious ^a	None	33/793 (4.2%)	33/785 (4.2%)	OR 0.90 (0.79–1.03)	4 fewer per 1000 (from 9 fewer to 1 more)
Functional outcome										
1	Randomised trials	Very serious ^b	Not serious	Not serious	Not serious	None	–/793	–/785	Not estimable	

CI: confidence interval; HR: hazard ratio; OR: odds ratio.

There were no data for major bleeding and intracranial bleeding outcomes.

^aSmall effect size and fails to rule out harm (confidence intervals cross over 1).^bStudy is at high risk of bias.^cSmall effect size and fails to rule out benefit (confidence intervals cross over 1).




Figure 7. Forest plot for the risk of haemorrhagic stroke in trials comparing treatment with HMGCoA reductase inhibitors versus placebo after TIA or stroke. $I^2 = 4.423$; $q = 2.093$, $p = 0.351$.




Figure 8. Forest plot for the risk of recurrent stroke in trials comparing treatment with PCSK9 inhibitors or ezetimibe versus placebo after TIA or stroke. Heterogeneity: $I^2 = 13.843$; Q -value = 2.321, $p = 0.313$.

reduction in the rate of dementia (OR 0.89, 95% CI 0.79–1.03). The level of certainty was rated as very low.

Additional information

Overall, we rated the quality of evidence as high. High quality evidence suggests that use of a HMGCoA reductase inhibitor reduces risk of ischaemic stroke and major cardiovascular events in people with previous ischaemic stroke or TIA. The effect on myocardial infarction in this population is less clear, although HMGCoA reductase inhibitors significantly reduce the risk of myocardial infarction in other groups. Our analysis showed that the risk of haemorrhagic stroke is increased with use of an HMGCoA reductase inhibitor. However, analysis showed

a trend towards a reduction in total stroke, and in cardiovascular death, suggesting a net beneficial effect in people with previous ischaemic stroke and TIA. It is important to note that the SPARCL trial included a small number of people with haemorrhagic stroke, but the increase in haemorrhagic stroke during follow-up was still seen when these participants were excluded from analyses. Therefore, even if this increase is real, our data show that use of an HMGCoA reductase inhibitor may cause six haemorrhagic strokes per 1000 people treated but prevent 40 major cardiovascular events. Participants in the SPARCL trial received atorvastatin 80 mg daily and when this is considered alongside the data for PICO question 6 below, we believe this is an appropriate dose for most people with ischaemic stroke or TIA.

PICO question 6: In people with ischaemic stroke or TIA does working to an intensive cholesterol treatment target, compared to a less intensive target, reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We found one randomised trial which directly addressed this PICO question. The Treat Stroke to Target trial included 2860 people with a stroke in the previous 3 months or a TIA within the previous 15 days.⁷² It was a parallel-group trial conducted in France and South Korea. Participants were randomised to an LDL target of <1.8 mmol/l (<70 mg/dl) or to a target LDL of 2.3 to 2.8 mmol/l (90–110 mg/dl). Investigators were allowed to use any type or dose of HMGCoA reductase inhibitor or other lipid lowering therapy to reach these targets. The primary outcome was occurrence of a major cardiovascular event. The median duration of follow up was 3.5 years. There was a higher rate of HMGCoA reductase inhibitor use (94% vs 66%) and a higher rate of combined HMGCoA reductase inhibitor and ezetimibe use (35% vs 6%) in the low target group. The study showed a significant reduction in the risk of major cardiovascular events (HR 0.78, 95% CI 0.61–0.98; $p=0.04$) in the intensive treatment group. There was a non-significant reduction in risk of cerebral infarction or intracranial haemorrhage (HR 0.82, 95% CI 0.63–1.07). There were also non-significant reductions in MI, (HR 0.64, 95% CI 0.37–1.13), cerebral infarction or TIA (HR 0.97, 95% CI 0.73–1.30), total mortality and cardiovascular mortality (HR 0.69, 95% CI 0.40–1.18). There was a non-significant increase in intracranial haemorrhage (HR 1.38, 95% CI 0.68–2.82).

Additional information

Post hoc analyses give further information concerning the benefits of intensive control of LDL cholesterol levels. Analysis from the Treat Stroke to Target trial showed that participants achieving LDL cholesterol <1.8 mmol/l (<70 mg/dl) had a lower risk of ischaemic stroke (OR 0.74, 95% CI 0.55–0.99).⁷² In a post-hoc analysis of the SPARCL trial,⁷¹ participants with a LDL cholesterol reduction of $\geq 50\%$ from baseline had a 35% reduction in the risk of all stroke (HR 0.65, 95% CI 0.52–0.81). In a post hoc analysis of the J-STARS study,⁷³ participants were divided into groups according to post-randomised LDL cholesterol levels (i.e. <2.1 mmol/l (80 mg/dl) ($n=89$), 2.1–2.6 mmol/l (80–100 mg/dl) ($n=319$), 2.6–3.1 mmol/l (100–120 mg/dl) ($n=478$), 3.1–3.6 mmol/l (120–140 mg/dl) ($n=419$), ≥ 3.6 mmol/l (140 mg/dl) ($n=212$)). The HR for stroke and TIA was lower with a post randomised LDL cholesterol level of 2.1 to 2.6 mmol/l (80–100 mg/dl) ($p=0.23$, for the trend) after adjustment for baseline LDL cholesterol, body

mass index, hypertension, diabetes mellitus and HMGCoA reductase inhibitor usage. Overall, we rated the level of certainty as moderate for this PICO question.

Evidence-based recommendation

In people with ischaemic stroke or TIA, we recommend aiming for an LDL cholesterol level of <1.8 mmol/l (70 mg/dl) to reduce the risk of major cardiovascular events.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 7: In people with a previous ischaemic stroke or TIA who do not achieve recommended LDL-C targets despite taking a maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or a PCSK9-inhibitor superior to an HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke?

Evidence-based recommendation

In people with previous ischaemic stroke or TIA we recommend use of a HMGCoA reductase inhibitor to reduce the risk of recurrent ischaemic stroke.

Quality of evidence: **High** ⊕⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We did not identify any randomised controlled trial that directly compared the add-on therapy with ezetimibe and/or PCSK-9 inhibitor versus HMGCoA reductase inhibitor alone in people with a history of ischaemic stroke or TIA. However, subgroup analyses of three randomised clinical trials, mostly in people with coronary heart disease^{74–76} have indirectly addressed the PICO question, albeit with limited precision due a small number of outcomes.

The Improved Reduction of Outcomes: Vytorin Efficacy International (IMPROVE-IT) trial⁷⁵ was a double-blinded, randomised trial involving 18,144 participants who were hospitalised for a recent acute coronary syndrome who had a LDL cholesterol level between 1.3 and 3.2 mmol/l (50 and 125 mg/dl) if not taking lipid lowering therapy or a LDL level between 1.3 and 2.6 mmol/l (50 and 100 mg/dl) if they were. Participants were randomised to ezetimibe plus simvastatin versus placebo plus simvastatin. Ezetimibe led to a significant relative reduction of major cardiovascular events (7-year risk 32.7% vs 34.7%; HR 0.94, 95% CI 0.89–0.99, $p=0.016$). The effect appeared to be consistent for any stroke (HR 0.86, 95% CI 0.73–1.00, $p=0.05$) and for ischaemic stroke (HR 0.79, 95% CI 0.67–0.94, $p=0.008$), without a significant increase in haemorrhagic stroke (HR 1.38, 95% CI 0.93–2.04, $p=0.11$). A small

number of participants ($n=682$, 3.8% of trial population) had a history of stroke at baseline.⁷⁷ The mean age was 68 years, with 29% being female. The baseline mean LDL was 87 mg/dl (2.2 mmol/l). In the subgroup of people with previous stroke, the results were consistent with the main analysis. There was a non-significant reduction of major cardiovascular disease with ezetimibe compared to placebo (HR 0.78, 95% CI 0.59–1.02). There was a significant reduction in risk of any stroke (HR 0.60, 95% CI 0.38–0.95), and ischaemic stroke (HR 0.52, 95% CI 0.31–0.86) but there were only 77 outcomes. There was no reduction in myocardial infarction (HR 0.85, 0.59–1.24), all-cause mortality (HR 0.96, 95% CI 0.71–1.30) or cardiovascular death (HR 1.11, 95% CI 0.70–1.76). There was no significant increase in haemorrhagic stroke (HR 1.69, 95% CI 0.40–7.06).

The Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY outcomes) trial was a multicentre, randomised, double-blind, placebo-controlled trial⁷⁴ comparing alirocumab, which is a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), versus placebo in 18,924 participants aged 40 years or older, who had been hospitalised with an acute coronary syndrome 1 to 12 months before randomisation. Baseline lipid levels were measured after a minimum of 2 weeks of treatment with moderate or high intensity HMGCoA reductase inhibitors or the maximum tolerated dose of these HMGCoA reductase inhibitors. Participants all had an LDL cholesterol level of at least 1.9 mmol/l (70 mg/dl), a non-HDL cholesterol level of at least 2.6 mmol/l (100 mg/dl) or an apolipoprotein B level of at least 80 mg/dl. The trial found that alirocumab reduced the risk of recurrent ischaemic cardiovascular events (4-year risk = 12.5% vs 14.5%; hazard ratio HR 0.85, 95% CI 0.73–0.98) compared to placebo. Moreover, alirocumab also reduced the risk of fatal or nonfatal ischaemic stroke by 27% (HR 0.73, 95% CI 0.57–0.93) without increasing the risk of haemorrhagic stroke (HR 0.83, 95% CI 0.42–1.65).⁷⁸ In ODYSSEY outcomes, there were 944 patients (5.0%) who also had a history of cerebrovascular disease at baseline.⁷¹ In this subgroup, the mean age was 63 years and approximately a third were women (31.9%). Baseline mean LDL was 91 mg/dl (2.4 mmol/l) and 84.7% were on a high-intensity HMGCoA reductase inhibitor. Although the trend was consistent with the overall study result, based on 51 outcomes, there was no significant reduction in stroke with alirocumab (HR 0.90, 95% CI 0.52–1.56).

The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial⁷⁶ was a multinational, randomised, double-blind, placebo-controlled trial comparing evolocumab, another monoclonal antibody that inhibits PCSK9, to placebo in 27,564 high-risk people aged 40 to 85 years with a history of myocardial infarction, non-haemorrhagic stroke or symptomatic peripheral artery disease. All participants had a baseline LDL of 70 mg/dl (1.8 mmol/l) or more, or a non-HDL cholesterol

level of at least 100 mg/dl (2.6 mmol/l) whilst on optimised lipid lowering therapy. In the whole intention-to-treat population, evolocumab reduced risks of major cardiovascular events by 15% (9.8% vs 11.3%; HR 0.85, 95% CI 0.79–0.92) compared to placebo. Of note, evolocumab was also associated with a 25% reduction in risks of ischaemic stroke (HR 0.75, 95% CI 0.62–0.92) without a significant increase in haemorrhagic stroke (HR 1.16, 95% CI 0.68–1.98). In line with the main results, among the subgroup of 5337 (19%) participants who had a history of ischaemic stroke at baseline (mean age 65 years, 22.2% female, mean LDL = 2.4 mmol/l), evolocumab was associated with a 15% reduction of major cardiovascular events (HR 0.85, 95% CI 0.72–1.00) compared to placebo, driven by a reduction in myocardial infarction (HR 0.74, 95% CI 0.55–1.00).⁷² However, based on 200 outcomes in total, there was no significant reduction in risk of recurrent stroke (HR 0.90, 95% CI 0.68–1.19), recurrent ischaemic stroke (HR 0.92, 95% CI 0.68–1.25), haemorrhagic stroke (HR 0.99, 95% CI 0.47–2.07) and cardiovascular death (HR 1.11, 95% CI 0.80–1.56).^{72,79}

Results for all considered outcomes and GRADE scoring, is available in Table 6.

On meta-analysis of data from the subgroup of participants with history of cerebrovascular disease from the above three trials,^{74–76} there was no significant reduction in any stroke with add-on therapy with ezetimibe and/or PCSK9-inhibitor (HR 0.81, 95% CI 0.64–1.04). The level of certainty was rated as low (Figure 8).

On meta-analysis of data from two trials,^{77,79} there was no significant reduction in ischaemic stroke (HR 0.72, 95% CI 0.41–1.25, Table 6) with add on therapy and there was no difference in rate of haemorrhagic stroke (HR 1.11, 95% CI 0.57–2.14; Table 6). The level of certainty for these outcomes was rated as low.

On meta-analysis of data from two trials,^{77,79} there was a significant reduction in major cardiovascular events (HR 0.83, 95% CI 0.72–0.96; Table 6, Figure 9) and myocardial infarction (HR 0.78, 95% CI 0.62–0.99; Table 6) with add on therapy. There was little evidence of heterogeneity, and the level of certainty was rated as high.

Additional information

As mentioned in PICO question 6, the recent Treat Stroke to Target trial showed that a lower target LDL cholesterol <70 mg/dl (1.8 mmol/l) was superior to a target of 90 to 110 mg/dl (2.3–2.8 mmol/l) for preventing major cardiovascular events in participants with ischaemic stroke or TIA with evidence of atherosclerosis.⁷² There is also evidence that each 1.0 mmol/l reduction in LDL (39 mg/dl) reduces the risks of major vascular events by about one-fifth.⁸⁰ This effect is also seen for the prevention of any stroke in wider populations of people at risk of cardiovascular disease.⁸¹ However, there is a lack of direct evidence in the stroke population. Overall, we rated the level of certainty as low.

Table 6. GRADE evidence profile for PICO question 7: In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or PCSK9-inhibitor superior to HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke?

Certainty assessment			No. of participants			Effect		Certainty	Importance			
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Addition of ezetimibe and/or PCSK9-inhibitor alone	To HMGCoA reductase inhibitor alone	Relative (95% CI)	Absolute (95% CI)		
Any stroke												
3	Randomised trials	Serious	Not serious	Not serious	Very serious ^a	None	149/3509 (4.2%)	179/3464 (5.2%)	HR 0.81 (0.64–1.04)	10 fewer per 1000 (from 18 fewer to 2 more)	⊕⊕○○ Low	Critical
Ischaemic stroke												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	103/3022 (3.4%)	130/2997 (4.3%)	HR 0.72 (0.41–1.25)	12 fewer per 1000 (from 25 fewer to 11 more)	⊕⊕○○ Low	Critical
Haemorrhagic stroke												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	19/3022 (0.6%)	17/2977 (0.6%)	HR 1.11 (0.57–2.14)	1 more per 1000 (from 2 fewer to 6 more)	⊕⊕○○ Low	Critical
Major adverse cardiovascular events												
2	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	352/3022 (11.6%)	417/2977 (14.0%)	HR 0.83 (0.72–0.96)	22 fewer per 1000 (from 37 fewer to 6 fewer)	⊕⊕⊕⊕ High	Critical
Myocardial infarction												
2	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	126/3022 (4.2%)	160/2977 (5.4%)	HR 0.78 (0.62–0.99)	12 fewer per 1000 (from 20 fewer to 1 fewer)	⊕⊕⊕⊕ High	Critical
Death												
1	Randomised trials	Serious ^c	Not serious	Not serious	Very serious ^a	None	83/336 (24.7%)	85/346 (24.6%)	HR 0.96 (0.71–1.30)	9 fewer per 1000 (from 64 fewer to 61 more)	⊕○○○ Very low	Critical
Cardiovascular death												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	111/3022 (3.7%)	99/2977 (3.3%)	HR 1.11 (0.85–1.46)	4 more per 1000 (from 5 fewer to 15 more)	⊕⊕○○ Low	Critical

CI: confidence interval; HR: hazard ratio.

There were no data for major bleeding, dementia, functional outcome and intracranial bleeding outcomes.

^aEffect size is small and fails to exclude appreciable harm (confidence intervals cross over 1).

^bEffect size is small and fails to exclude benefit (confidence intervals cross over 1).

^cUncertain risk of bias in study.




Figure 9. Forest plot for the risk of any major cardiovascular event in trials comparing treatment with PCSK9 inhibitors versus placebo after TIA or stroke. Heterogeneity: $I^2=0.000$; $Q=0.278$; $p=0.598$.

Supporting information to the expert consensus statement

There is insufficient evidence to support a recommendation concerning add-on therapy with ezetimibe and/or PCSK9-inhibitor to reduce risk of recurrent stroke in people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks. This was due to imprecision and potential selection bias as all data are derived from subgroup analyses of trials. However, there is some evidence, albeit indirect for the TIA and ischaemic stroke population, that the addition of ezetimibe and/or PCSK-9 inhibitor is superior to HMGCoA reductase inhibitor alone to reduce the overall risk of recurrent major cardiovascular events in this population. Moreover, there is evidence that a more intensive cholesterol treatment target compared to a less intensive target, which includes use of ezetimibe in some people, reduces the risk of recurrent ischaemic stroke and major cardiovascular events. The use of a PCSK9 inhibitor could be considered in people who have ischaemic heart disease, or who have ischaemic stroke and would have met the criteria for the FOURIER trial, where LDL targets cannot be obtained using a HMGCoA reductase inhibitor and ezetimibe. The panel voted by 12/12 members for the following consensus statement (Supplemental Table 2).

Evidence-based recommendation

–

Quality of evidence: –

Strength of recommendation: –

Expert consensus statement

In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, we support the addition of ezetimibe as an option to reduce the risk of recurrent major cardiovascular events.

In adult people with ischaemic stroke or TIA there is continued uncertainty over the use of ezetimibe and/or PCSK9-inhibitors to reduce risk of recurrent stroke.

Anti-thrombotic therapy

PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet therapy reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified for review. For this PICO question, 11 studies and a total of 13,369 participants were included.^{82–92} Eight trials compared aspirin to placebo,^{82–89} one trial compared cilostazol with placebo⁹² and one compared ticlopidine versus placebo.⁹¹ One trial compared aspirin and dipyridamole to placebo⁸⁷ and one trial included an aspirin and dipyridamole arm as well as an aspirin monotherapy arm.⁹⁰ For our quantitative synthesis we only included data on antiplatelet monotherapy in our primary analysis as the use of dual antiplatelet therapy was addressed in PICO question 9. We explored whether inclusion of data from the European Stroke Prevention Study (ESPS) trial would materially alter the conclusions in an additional analysis because this compared aspirin and dipyridamole with placebo. Time from index event to inclusion in the study ranged from 1 week to 1 year, with the majority being within 3 months. Follow-up ranged between 2 and 7 years (mean 2 years). The dose of aspirin used ranged from 50 to 1300 mg daily.

The Trial of Aspirin in Transient Ischaemia (AITIA) Trial⁸² was a double-blind RCT including 178 participants with a TIA or retinal occlusion who were randomised to either aspirin 1300 mg or placebo. The primary outcome was mortality, cerebral or retinal infarction and follow-up was for 2 years. There was no difference between groups in the rate of the primary outcome.

The Canadian cooperative study^{83,84} was a double-blind RCT including 585 participants with 'threatened stroke' who were randomised to either aspirin 1300 mg, sulfinpyrazone 800 mg, both these drugs or placebo. The mean follow-up was 26 months and the primary outcome was TIA, stroke or death. There was a significant reduction in the primary outcome in the aspirin group.

The Accidents Ischémiques Cerebraux Lies a L'Atherosclerose (AICLA) trial⁸⁴ was a three arm double blind study in people with a recent TIA or cerebral infarction. Participants were randomised to receive either aspirin (1000 mg), aspirin and dipyridamole (1000 mg + 225 mg) or placebo. Follow-up was for 3-year and the primary outcome was cerebral infarction. Treatment with aspirin and treatment with aspirin plus dipyridamole reduced the risk of stroke compared to placebo.

The Danish cooperative study⁸⁵ was a randomised double-blinded study of 203 participants comparing aspirin (1000 mg) with placebo. Mean follow-up was 25-month and the primary outcome was stroke or death. The study did not find any statistical difference between groups.

The Swedish cooperative study⁸⁶ was a double-blind placebo controlled trial of 1500 mg aspirin daily versus placebo in 505 participants within 3-week of cerebral infarction. Participants were followed for up to 2 years and the primary outcome were stroke or death. The study showed no difference between groups.

The UK-TIA trial⁸⁸ randomised 2435 participants with TIA or minor stroke to either aspirin 300 or 1200 mg or placebo in a double-blinded study with a mean follow-up of 4 years. The primary outcome was major stroke, myocardial infarction and vascular death. There was a significant reduction in the primary endpoint with aspirin treatment.

The Swedish Aspirin Low-Dose Trial (SALT) collaboration⁸⁹ was a double-blinded study which randomised participants to aspirin (75 mg) versus placebo. The mean duration of follow up was 32 months. The primary outcome was occurrence of stroke or death and there was a significant reduction with aspirin treatment.

ESPS 2⁹⁰ was a four-arm double-blinded randomised trial of aspirin 50 mg, dipyridamole 400 mg, aspirin plus dipyridamole (50 + 400 mg) or placebo. Follow up was for 2 years and the primary endpoint was stroke or death. The study found a significant benefit of all the antiplatelet strategies.

The Canadian American ticlopidine study (CATS) randomised 1072 people between 1 week and 4 months after an ischaemic stroke to ticlopidine (250 mg bd) or placebo, for up to 3 years.⁹¹ The primary outcome was a composite of stroke, myocardial infarction or vascular death. There was a significant reduction in the primary outcome from 15.3% in the placebo group to 10.8% in the ticlopidine group (RRR 30.2%, 95% CI 7.5–48.3, $p=0.006$).

The ESPS study⁸⁷ randomised 2500 participants to either aspirin 990 mg plus dipyridamole 225 mg or placebo in a double blinded study. Participants were followed for 2-year,

and the primary outcome was stroke or death. There was a significant reduction in the primary outcome with aspirin and dipyridamole.

The cilostazol stroke prevention study (CSPS) was a double-blind randomised trial testing cilostazol versus placebo⁹² on 1095 participants. The primary outcome was recurrence of cerebral infarction. There was a 41.7% relative risk reduction with cilostazol (95% CI 9.2–62.5, $p=0.015$).

Results from meta-analysis for all outcomes and GRADE scoring, is available in Table 7. On meta-analysis of data from nine trials^{82,84–86,88–92} antiplatelet therapy reduced the risk of any stroke (OR 0.82, 95% CI 0.73–0.92, $I^2=0\%$, Figure 10, Table 7). The level of certainty was rated as high. Use of an antiplatelet would be expected to lead to 24 fewer cases of stroke per 1000 treated.

On meta-analysis of data from five trials,^{82,84–86,89} antiplatelet therapy reduced the risk of ischaemic stroke (OR 0.67, 95% CI 0.54–0.85, $I^2=11.4\%$, $p=0.001$, Table 7).

On meta-analysis of data from seven trials,^{84,86,88–92} antiplatelet therapy reduced the risk of major cardiovascular events (OR 0.78, 95% CI 0.67–0.90, $I^2=44\%$, Figure 11, Table 7).

On meta-analysis of data from four trials^{82,84,86,89} including 2718 participants, antiplatelet therapy did not significantly increase the risk of haemorrhagic stroke (OR 1.93, 95% CI 0.78–4.76, $I^2=0\%$, Table 7) but the level of certainty was rated as low. On meta-analysis of data from three trials,^{89–91} antiplatelet therapy increased the risk of a major bleeding episode (OR 2.51, 95% CI 1.42–4.42, $I^2=0\%$, $p=0.002$, Table 7). Use of an antiplatelet would be expected to lead to nine more cases of major bleeding per 1000 treated.

On meta-analysis of data from nine trials,^{82,84–86,88–92} antiplatelet therapy reduced the risk of myocardial infarction (OR 0.77, 95% CI 0.61–0.98, $I^2=0\%$, $p=0.56$ Table 7). On meta-analysis of data from 10 trials^{82–85,87–92} including 10,869 participants, antiplatelet therapy did not significantly reduce the risk of death (OR 0.90, 95% CI 0.80–1.02, $I^2=0\%$, $p=0.107$, Table 7). On meta-analysis of data from nine trials^{82–86,88,89,91,92} including 7471 participants, antiplatelet therapy did not significantly reduce the risk of cardiovascular death (OR 0.94, 95% CI 0.79–1.13, $I^2=0\%$, Table 7) or improve functional outcome (OR 1.01, 95% CI 0.72–1.42). There were no data concerning the effect on risk of dementia.

Additional information

Most of the included studies tested aspirin antiplatelet therapy. Previous other meta-analyses have found results consistent with our findings. In 1994, the Antiplatelet Trialists Collaboration published a collaborative and comprehensive overview of antiplatelet therapy trials up to March 1990.⁹³ They concluded there was a significant benefit from antiplatelet use in people with stroke and found the optimal

Table 7. GRADE evidence profile for PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet treatment reduce the risk of recurrent stroke?

Certainty assessment			No. of participants			Effect		Certainty	Importance			
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Long-term antiplatelet therapy	No antiplatelet treatment	Relative (95% CI)	Absolute (95% CI)		
Any stroke												
9	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	681/5255 (13.0%)	689/4462 (15.4%)	OR 0.82 (0.73–0.92)	24 fewer per 1000 (from 37 fewer to 10 fewer)	⊕⊕⊕⊕ High	Critical
Ischaemic stroke												
5	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	167/1714 (9.7%)	237/1756 (13.5%)	OR 0.67 (0.54–0.85)	39 fewer per 1000 (from 58 fewer to 17 fewer)	⊕⊕⊕⊕ High	Critical
Haemorrhagic stroke												
4	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	14/1215 (1.2%)	7/1230 (0.6%)	OR 1.93 (0.78–4.76)	5 more per 1000 (from 1 fewer to 21 more)	⊕⊕○○ Low	Critical
Major cardiovascular events												
7	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	993/5458 (18.2%)	997/4657 (21.4%)	OR 0.78 (0.67–0.90)	39 fewer per 1000 (from 59 fewer to 17 fewer)	⊕⊕⊕⊕ High	Critical
Myocardial infarction												
6	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	127/3403 (3.7%)	164/3427 (4.8%)	OR 0.77 (0.61–0.98)	11 fewer per 1000 (from 18 fewer to 1 fewer)	⊕⊕⊕⊕ High	Critical
Death												
10	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	600/5881 (10.2%)	538/4988 (10.8%)	OR 0.90 (0.80–1.02)	10 fewer per 1000 (from 20 fewer to 2 more)	⊕⊕○○ Low	Critical
Cardiovascular death												
9	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	305/4132 (7.4%)	232/3339 (6.9%)	OR 0.94 (0.79–1.13)	4 fewer per 1000 (from 14 fewer to 9 more)	⊕⊕○○ Low	Critical
Any major bleeding episode												
3	Randomised trials	Not serious	Not serious	Not serious	Serious ^c	None	42/2850 (1.5%)	17/2861 (0.6%)	OR 2.51 (1.42–4.43)	9 more per 1000 (from 2 more to 20 more)	⊕⊕⊕○ Moderate	Critical
Functional outcome												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^a	None	100/1722 (5.8%)	54/916 (5.9%)	OR 1.01 (0.72–1.42)	1 more per 1000 (from 16 fewer to 23 more)	⊕⊕○○ Low	Important

CI: confidence interval; OR: odds ratio.

^aFails to rule out benefit. Confidence intervals cross 1.0.^bFails to rule out harm. Confidence intervals cross 1.0.^cLimited sample size/number of events. There were no data for the outcome dementia.




Figure 10. Forest plot for the risk of any stroke in trials comparing treatment with an antiplatelet versus placebo after TIA or stroke. $I^2=0.000$; $q=6.075$, $p=0.639$. With ESPS1 included, OR=0.78 (0.68–0.89).




Figure 11. Forest plot for the risk of major cardiovascular events in trials comparing treatment with an antiplatelet versus placebo after TIA or stroke. $I^2=44.134$; $q=10.740$; $p=0.097$.

dose of aspirin was 75 to 325 mg/day based on limited additional benefit of higher doses but increased bleeding risk. Our results were similar with and without inclusion of data from the ESPS trial.

Since these studies were conducted, a number of new antiplatelets have been developed and studied in people with stroke. Broadly, these studies suggest that they are of at least similar benefit to aspirin. For example, in the PROFESS trial, there was a similar rate of recurrent stroke with aspirin and dipyridamole (9%) than with clopidogrel (8.8%) (HR 1.01, 95% CI 0.92–1.11). Our recommendations cover use of antiplatelet therapy generally and choice of drug regimen may differ in some

regions. Overall, we rated the quality of evidence as being moderate as, while it was high for any stroke, ischaemic stroke and major cardiovascular events, it was low for haemorrhagic stroke due to imprecision and moderate for major bleeding.

Evidence-based recommendation

In people with previous ischaemic stroke or TIA, we recommend long-term use of antiplatelet therapy to reduce the risk of recurrent stroke.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified. For this specific PICO question, six studies^{90,94–98} and a total of 41,309 participants were included in the qualitative and quantitative synthesis. This PICO question does not address use of dual antiplatelets early after minor ischaemic stroke and TIA.

The Management of Atherothrombosis with Clopidogrel in High-risk patients (MATCH) trial⁹⁴ enrolled 7599 people with ischaemic stroke or TIA in the previous 3 months, with one or more of five risk factors (history of ischaemic stroke, history of myocardial infarction, angina pectoris, diabetes mellitus symptomatic peripheral arterial disease). Participants were randomised to clopidogrel 75 mg daily and aspirin 75 mg daily or clopidogrel 75 mg daily and placebo. The duration of follow-up was 18 months. In the dual antiplatelet (DAPT) arm, the RRR for any stroke was 2.0% (95% CI –13.8 to 15.6), for ischaemic stroke was 7.1% (95% CI –8.5 to 20.4) and for major cardiovascular events was 5.9% (95% CI –7.1 to 17.3). The absolute risk increase in major bleeding was 1.36% (95% CI 0.86–1.86).

Two trials^{95,96} compared aspirin and clopidogrel with aspirin and placebo. The Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation Management and Avoidance (CHARISMA) trial⁹⁵ enrolled 15,603 people with multiple atherothrombotic risk factors, coronary disease, cerebrovascular disease symptomatic peripheral arterial disease. Participants were randomised to aspirin in a daily dose ranging from 75 to 162 mg and clopidogrel 75 mg daily or aspirin and placebo. In participants with cerebrovascular disease, median follow-up was 2.1 years. In the DAPT arm, the HR for any stroke was 0.80 (95% CI 0.62–1.03), for ischaemic stroke it was 0.80 (95% CI 0.60–1.05), for haemorrhagic stroke it was 1.11 (95% CI 0.45–2.74) and for major cardiovascular events it was 0.84 (95% CI 0.69–1.03). The SPS3 trial⁹⁶ enrolled people with a recent lacunar infarct. Participants were randomised to aspirin 325 mg daily and clopidogrel 75 mg daily or aspirin 325 mg daily and placebo. The mean duration of follow-up was 3.4 years. In the DAPT arm, HR for any stroke was 0.92 (95% CI 0.72–1.16), for ischaemic stroke it was 0.82 (95% CI 0.63–1.09), for haemorrhagic stroke it was 1.65 (95% CI 0.83–3.31) and for major cardiovascular events it was 0.89 (95% CI 0.72–1.11).

Three trials^{90,97,98} compared aspirin and extended-release (ER) dipyridamole versus single antiplatelet therapy. The PROfESS trial⁹⁸ enrolled 20,322 people with an ischaemic stroke within the prior 3 months. Participants were randomised to aspirin 25 mg daily and dipyridamole 200 mg

twice daily or clopidogrel 75 mg daily. The median duration of follow-up was 25 months for participants with cerebrovascular disease. In the DAPT arm, the HR for any stroke was 1.01 (95% CI 0.92–1.11), for ischaemic stroke it was 0.80 (95% CI 0.60–1.05), for intracranial haemorrhage it was 1.42 (95% CI 1.11–1.83) and for major cardiovascular events it was 0.99 (95% CI 0.92–1.07).

The ESPS-2 trial⁹⁰ enrolled 6602 people with ischaemic stroke or TIA within the preceding 3 months. Participants were randomised to aspirin 50 mg daily, or modified-release dipyridamole 400 mg daily, both these drugs combined, or placebo. In the original publication, stroke was not divided into haemorrhagic and ischaemic subtypes. Here, we consider the comparison of aspirin combined with dipyridamole versus aspirin alone. We computed the ORs based on the crude rates published. In the DAPT arm, compared to aspirin alone, the OR for any stroke was 0.74 (95% CI 0.59–0.92) and for major cardiovascular events it was 0.74 (95% CI 0.61–0.90).⁹⁰

The European/Australasian Stroke Prevention in Reversible Ischaemia (ESPRIT) trial⁹⁷ enrolled 2739 people within 6 months of a non-disabling ischaemic stroke and TIA. Participants were randomised to aspirin (30–325 mg daily) and dipyridamole 400 mg daily or aspirin alone. The mean duration of follow up was 3.5 years. In the DAPT arm, the OR for ischaemic stroke was 0.82 (95% CI 0.62–1.09), the OR for major adverse cardiovascular events was 0.76 (95% CI 0.60–0.95) and the OR for death was 0.87 (95% CI 0.65–1.16).

Results for meta-analysis of all outcomes and GRADE scoring are shown in Table 8. In the meta-analysis including five randomised controlled trials,^{90,94–96,98} use of dual antiplatelets did not significantly reduce the risk of recurrent stroke (Figure 12, Table 8), but there was a significant reduction in the risk of ischaemic stroke (OR=0.92, 95% CI 0.85–0.99, Table 8). The level of certainty was rated as very low due to imprecision and inconsistency.

However, in three randomised controlled trials,^{95,96,98} use of dual antiplatelets was associated with a significantly increased risk of haemorrhagic stroke (Figure 13; Table 8). The level of certainty was rated as high. The use of DAPT would be expected to lead to four more cases of haemorrhagic stroke per 1000 treated.

Additional information

Overall, we rated the quality of evidence as being very low. Three trials assessed clopidogrel and aspirin dual anti-platelet therapy and three assessed aspirin and dipyridamole dual anti-platelet therapy. There was no evidence of net benefit of dual anti-platelet therapy in the trials of clopidogrel and aspirin therapy. There was no benefit of aspirin and dipyridamole therapy compared to clopidogrel in the PROfESS trial but risk of intracerebral haemorrhage was increased. Adverse events and discontinuation of treatment were also more common with aspirin and

Table 8. GRADE evidence profile for PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke?.

Certainty assessment				No. of participants		Effect		Certainty	
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Single antiplatelet	Relative (95% CI)	Absolute (95% CI)
<i>Any stroke</i>									
5	Randomised trials	Not serious	Serious ^a	Not serious	Very serious ^b	None	1642/19,302 (8.5%)	OR 0.90 (0.80–1.02)	8 fewer per 1000 (from 17 fewer to 2 more)
<i>Ischaemic stroke</i>									
5	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	1385/19,015 (7.3%)	OR 0.92 (0.85–0.99)	6 fewer per 1000 (from 11 fewer to 1 fewer)
<i>Haemorrhagic stroke</i>									
3	Randomised trials	Not serious	Not serious	Not serious	Not serious	None	178/13,855 (1.3%)	OR 1.42 (1.13–1.78)	4 more per 1000 (from 1 more to 7 more)
<i>Major adverse cardiovascular events</i>									
6	Randomised trials	Not serious	Serious ^a	Not serious	Not serious	None	2460/20,665 (11.9%)	OR 0.87 (0.78–0.97)	15 fewer per 1000 (from 25 fewer to 4 fewer)
<i>Myocardial infarction</i>									
5	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	360/19,302 (1.9%)	OR 0.96 (0.83–1.11)	1 fewer per 1000 (from 3 fewer to 2 more)
<i>Death</i>									
5	Randomised trials	Not serious	Serious ^a	Not serious	Very serious ^c	None	1331/18,508 (7.2%)	OR 1.03 (0.90–1.17)	2 more per 1000 (from 7 fewer to 11 more)
<i>Cardiovascular death</i>									
4	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	659/17,498 (3.8%)	OR 0.92 (0.83–1.03)	3 fewer per 1000 (from 7 fewer to 1 more)
<i>Intracranial bleeding</i>									
4	Randomised trials	Not serious	Not serious	Not serious	Very serious ^c	None	87/16,811 (0.5%)	OR 1.22 (0.81–1.83)	1 more per 1000 (from 1 fewer to 4 more)
<i>Any major bleeding episode</i>									
6	Randomised trials	Not serious	Very serious ^a	Not serious	Very serious ^c	None	700/20,627 (3.4%)	OR 1.39 (0.95–2.02)	10 more per 1000 (from 1 fewer to 26 more)
<i>Functional outcome</i>									
1	Randomised trials	Not serious	Not serious	Not serious	Very serious ^c	None	42/1517 (2.8%)	HR 1.06 (0.69–1.64)	2 more per 1000 (from 8 fewer to 17 more)

CI: confidence interval; HR: hazard ratio; OR: odds ratio.

^aSignificant degree of heterogeneity according to I^2 .^bFails to rule out harm. Confidence intervals cross 1.0.^cFails to rule out benefit. Confidence intervals cross 1.0. There were no data for the outcome dementia.




Figure 12. Forest plot for the risk of recurrent stroke in trials comparing treatment with dual versus single antiplatelets for more than 90 days after TIA or stroke. Heterogeneity $I^2 = 57.089$; $q = 9.322$, $p = 0.054$.




Figure 13. Forest plot for the risk of haemorrhagic stroke in trials comparing treatment with dual versus single antiplatelets for more than 90 days after TIA or stroke.

dipyridamole. The ESPRIT and ESPS-2 trials showed benefit from aspirin and dipyridamole compared to aspirin for some outcomes. Network meta-analyses have attempted to establish the best long-term anti-platelet therapy and suggest that clopidogrel or aspirin and dipyridamole in combination are the best strategies.⁹⁹ We performed additional analyses to assess whether the effect of dual antiplatelet therapy with aspirin and clopidogrel appears similar to that of aspirin and dipyridamole. Note there are no head-to-head comparisons of these strategies. Results were broadly consistent for the outcomes of any stroke and haemorrhagic stroke but rates of any major bleeding episode with aspirin and clopidogrel were higher than with monotherapy (Supplemental Figures 2 and 3). However, these analyses were limited by heterogeneity.

Overall, we conclude that the evidence favours use of antiplatelet monotherapy and indirect data suggest that clopidogrel is preferable to aspirin. Local practice regarding the choice of agent differs across Europe.

Evidence-based recommendation

In people with previous ischaemic stroke or TIA, we recommend against use of dual antiplatelet therapy with aspirin and clopidogrel in the long-term and recommend use of single antiplatelet to reduce the risk of recurrent stroke.

Quality of evidence: **Very low** ⊕

Strength of recommendation: **Weak against intervention** ↓?

PICO Question 10: In people with ischaemic stroke or TIA and atherosclerosis, with no other indication for anticoagulation, does antiplatelet therapy combined with a low-dose direct oral anticoagulant compared to antiplatelet therapy alone reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified. No randomised trials were found which directly addressed this PICO question in this population.

One trial addressed this treatment in people with other types of cardiovascular disease. The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) included 27,395 people with stable atherosclerotic disease.¹⁰⁰ Participants had either a history of coronary artery disease or peripheral vascular disease. Participants with coronary artery disease who were <65 years of age were required to have arterial disease in two vascular beds or have two additional risk factors, one of which could be non lacunar ischaemic stroke >1 month ago. The definition of peripheral arterial disease included history of previous carotid revascularisation or an asymptomatic carotid artery stenosis of >50%.

People with a history of stroke within 1 month or any history of haemorrhagic or lacunar stroke were excluded. In total, 3.8% of trial participants had a history of previous stroke. A total of 7470 people were enrolled with a history of peripheral vascular disease and 26% of these had a history of previous carotid artery disease or asymptomatic carotid artery stenosis >50%.

The trial compared three treatment strategies. These were rivaroxaban 2.5mg twice daily plus aspirin 100mg, rivaroxaban 5mg twice daily and aspirin 100mg daily. The combination of rivaroxaban plus aspirin reduced the risk of the primary outcome of cardiovascular death, stroke myocardial infarction compared to aspirin alone (HR 0.76, 95% CI 0.66–0.86, $p < 0.001$). Rivaroxaban was not superior to aspirin alone. The risk of stroke was reduced by the combination of rivaroxaban plus aspirin compared to aspirin alone (HR 0.58, 95% CI 0.44–0.76) with an absolute risk reduction of 0.7%. The risk of ischaemic stroke was also reduced (HR 0.51, 95% CI 0.38–0.68). There was no significant increase in the risk of haemorrhagic stroke (HR 1.49, 95% CI 0.67–3.31) but there were few events and a potentially important increase cannot be excluded. An exploratory analysis showed that the combination of rivaroxaban plus aspirin reduced the risk of cardioembolic stroke and embolic stroke of undetermined source.¹⁰¹ In subgroup analyses of participants with a history of peripheral artery disease, and in those with carotid artery disease, the results were consistent with those from the whole study population.¹⁰² In a subgroup analysis of people with previous stroke results were also similar but this was based on a small number of events ($n = 29$).¹⁰³

A recent systematic review and meta-analysis on low dose direct oral anticoagulation therapy combined with antiplatelet therapy in people with cardiovascular disease

included seven randomised trials.¹⁰⁴ In addition to the COMPASS trial, three of these trials included people with acute coronary syndrome^{105–107}, one included people with heart failure,¹⁰⁸ one included people with peripheral arterial disease¹⁰⁹ and one included people with atrial fibrillation¹¹⁰ (although in this trial antiplatelet use was not protocol defined). There was a trend towards a reduction in risk of stroke on meta-analysis (IRR 0.73, 95% CI 0.53–1.01, random effects model) with combination therapy. There was no increased risk of intracranial haemorrhage. None of these trials has reported results for the subgroup of people with history of stroke and people with stroke or recent stroke were excluded.

Supporting information for consensus statement

Overall, we rated the quality of evidence as low due to indirectness; there is no direct evidence to support a recommendation for use of antiplatelet therapy combined with a low-dose direct oral anticoagulant in people with a history of ischaemic stroke or TIA. In particular, it is important to note that people with ischaemic stroke within the past month were excluded from the COMPASS trial. However, many people with stroke have a history of coronary artery disease or peripheral arterial disease. The effect in people with carotid artery disease was also consistent with the main trial results. The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant may be an appropriate option for some people with a history of ischaemic stroke or TIA, more than 1 month previously, if they have co-existing coronary or peripheral arterial disease and this is being used to optimise treatment of these conditions. Note that only rivaroxaban has been studied in this context so other DOACs should not be used for this purpose. The panel voted by 12/12 members for the following consensus statement (Supplemental Table 2).

Evidence-based recommendation

–

Quality of evidence: –

Strength of recommendation: –

Expert consensus statement

The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant (rivaroxaban) can be considered to optimise treatment of coronary artery disease or peripheral arterial disease in people with a history of ischaemic stroke or TIA more than 1 month previously. It should not be considered in people with ischaemic stroke or TIA who do not have coronary artery disease or peripheral arterial disease.

In adult people with ischaemic stroke or TIA there is continued uncertainty over the use of antiplatelet therapy combined with a low-dose direct oral anticoagulant.

PICO Question 11: In people with an embolic stroke of undetermined source (ESUS) does treatment with a direct oral anticoagulant drug compared to an antiplatelet reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified. For this specific PICO question, two studies and a total of 12,603 participants were included in the qualitative and quantitative synthesis. These two studies were randomised clinical trials comparing a DOAC to an antiplatelet to reduce the risk of stroke in people with ESUS.

The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial is a multicenter, double-blinded, randomised trial which compared rivaroxaban 15mg once daily with aspirin 100mg once daily in 7213 people with recent (between 7 days and 6 months) ESUS.¹¹¹ The mean follow-up duration was 2 years. In this trial, ESUS was defined as non-lacunar ischaemic stroke, not associated with extracranial vessel atherosclerosis causing more than 50% luminal stenosis in arteries supplying the area of ischaemia, or with identified risk factors for a cardiac source of embolism. The use of rivaroxaban did not reduce the risk of recurrent stroke compared to aspirin (HR 1.08, 95% CI 0.87–1.34, $p=0.47$). Major bleeding was increased with rivaroxaban (HR 2.72, 95% CI 1.68–4.39, $p<0.001$). The trial was stopped prematurely because of a lack of benefit on stroke risk and bleeding associated with rivaroxaban.

The Randomised, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etxilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (RESPECT ESUS) trial is a multicenter, randomised, double-blind trial which compared dabigatran 150 or 110mg (for participants aged ≥ 75 years and/or with creatinine clearance 30 to <50 ml/minute) twice daily with aspirin 100mg once daily in 5390 people who had experienced an ESUS within the prior 3 months (or within the prior 6 months if they had at least one additional vascular risk factor, or if they were aged 18–59 years (20–59 in Japan) and had at least one additional vascular risk factor).¹¹² The median follow-up duration was 19 months. The definition of ESUS was similar to that used in NAVIGATE. In this trial, dabigatran was not superior to aspirin in preventing stroke (HR 0.85, 95% CI 0.69–1.03, $p=0.10$) or ischaemic stroke. Major bleeding was not increased with dabigatran (HR 1.19, 95% CI 0.85–1.66).

Results for meta-analysis of all outcomes and GRADE scoring is available in Table 9. On meta-analyses of data from these two trials, there was no difference in the rate of any stroke (OR 0.96, 95% CI 0.75–1.22, Table 9). The level of certainty was rated as low. There was also no difference

in the rate of ischaemic stroke (OR 0.92, 95% CI 0.76–1.10, Table 9). The rate of haemorrhagic stroke was increased in one trial but on meta-analysis of data from the two trials, the rate of intracranial bleeding (OR 1.87, 95% CI 0.48–7.26, Table 8) and major bleeding episodes (OR 1.78, 95% CI 0.80–3.94, Table 8) were not significantly increased (Table 9).

Additional information

There is no evidence to suggest DOAC in preference to antiplatelets in people with ESUS as defined in the RESPECT and NAVIGATE trials. Although a DOAC was equally effective with regard to rate of stroke, bleeding risk was increased in one trial and point estimates for any stroke were inconsistent in the two trials. Overall, we rated the quality of evidence as low. Ongoing trials are investigating whether use of serum, ECG or echocardiographic biomarkers can identify people with ischaemic stroke who do benefit from a DOAC.¹¹³ However, one trial which adopted this approach, the Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) trial, was stopped early due to futility.

Evidence-based recommendation

In people with an embolic stroke of undetermined source, we suggest use of antiplatelet therapy and not a DOAC to reduce the risk of recurrent stroke.

Quality of evidence: **Low** ⊕⊕

Strength of recommendation: **Weak against intervention**
↓?

Diabetes mellitus

PICO Question 12: In people with diabetes mellitus and ischaemic stroke or TIA, does intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control reduce the risk of recurrent stroke?

Analysis of current evidence

People with diabetes mellitus are at a two-folds increased risk of stroke and the relative risk of stroke is reported to increase by approximately 15% with each 1% increase in glycated haemoglobin (HbA1c) level.^{114,115} Intensive control of blood glucose levels in people with diabetes reduces the risk of microvascular complications such as retinopathy, nephropathy and neuropathy. However, it is less certain whether intensive control lowers risk of major cardiovascular events, including stroke.

Our systematic review literature search identified 1286 titles and 138 full texts were screened. For this specific PICO question, we were unable to identify any randomised

Table 9. GRADE evidence profile for PICO question 11: In people with an embolic stroke of undetermined source does treatment with a DOAC compared to an antiplatelet reduce the risk of recurrent stroke?

Certainty assessment				No. of participants		Effect		Certainty	Importance			
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment with a DOAC	An antiplatelet	Absolute (95% CI)	Relative (95% CI)		
Any stroke												
2	Randomised trials	Not serious	Serious ^a	Not serious	Serious ^b	None	348/6304 (5.5%)	365/6299 (5.8%)	2 fewer per 1000 (from 14 fewer to 12 more)	OR 0.96 (0.75–1.22)	⊕⊕○○ Low	Critical
Ischaemic stroke												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	330/6304 (5.2%)	359/6229 (5.8%)	5 fewer per 1000 (from 13 fewer to 6 more)	OR 0.92 (0.76–1.10)	⊕⊕○○ Low	Critical
Haemorrhagic stroke												
1	Randomised trials	Not serious	Not serious	Not serious	Serious ^c	None	13/3609 (0.4%)	2/3604 (0.1%)	3 more per 1000 (from 0 fewer to 15 more)	HR 6.50 (1.47–28.80)	⊕⊕⊕○ Moderate	Critical
Major adverse cardiovascular events												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	414/6304 (6.6%)	427/6229 (6.9%)	2 fewer per 1000 (from 10 fewer to 7 more)	OR 0.97 (0.84–1.11)	⊕⊕○○ Low	Critical
Myocardial infarction												
1	Randomised trials	Not serious	Not serious	Not serious	Very serious ^b	None	17/3609 (0.5%)	23/3604 (0.6%)	2 fewer per 1000 (from 4 fewer to 2 more)	HR 0.74 (0.39–1.38)	⊕⊕○○ Low	Critical
Death												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^d	None	121/6304 (1.9%)	110/6229 (1.8%)	2 more per 1000 (from 3 fewer to 7 more)	OR 1.10 (0.85–1.43)	⊕⊕○○ Low	Critical
Cardiovascular death												
2	Randomised trials	Not serious	Not serious	Not serious	Very serious ^d	None	37/3903 (0.9%)	24/3904 (0.6%)	3 more per 1000 (from 1 fewer to 10 more)	OR 1.54 (0.92–2.58)	⊕⊕○○ Low	Critical
Intracranial bleeding												
2	Randomised trials	Not serious	Very serious ^a	Not serious	Very serious ^d	None	52/6303 (0.8%)	37/6229 (0.6%)	5 more per 1000 (from 3 fewer to 36 more)	OR 1.87 (0.48–7.26)	⊕○○○ Very low	Critical
Any major bleeding episode												
2	Randomised trials	Not serious	Very serious ^a	Not serious	Very serious ^d	None	139/6303 (2.2%)	87/6229 (1.4%)	11 more per 1000 (from 3 fewer to 39 more)	OR 1.78 (0.80–3.94)	⊕○○○ Very low	Critical
Functional outcome												
2	Randomised trials	Not serious	Very serious ^a	Not serious	Very serious ^b	None	66/6303 (1.0%)	73/6229 (1.2%)	1 fewer per 1000 (from 7 fewer to 14 more)	OR 0.90 (0.36–2.21)	⊕○○○ Very low	Important

CI: confidence interval; HR: hazard ratio; OR: odds ratio.

^aConsiderable heterogeneity according to I^2 .^bFails to rule out harm. Confidence intervals cross 1.0.^cSmall sample/event size.^dFails to rule out benefit. Confidence intervals cross 1. There were no data for the outcome dementia.

controlled trials specifically designed to test the effect of the intensive control of glycaemia on risk of recurrent stroke in people with ischaemic stroke or TIA and diabetes mellitus.

Several trials have reported the effect of intensive glycaemic control on cardiovascular events in other populations of people with diabetes mellitus. The UK Prospective Diabetes Study (UKPDS) included 4209 people with newly diagnosed type 2 diabetes, with a median age of 53 years.¹¹⁶ Only 2% of participants had a history of myocardial infarction and 1% had a history of stroke or TIA on enrolment. Participants were randomly assigned to either a diet policy, with the aim of maintaining a fasting plasma glucose level of <15 mmol/l, or to an active policy, with the aim of maintaining fasting plasma glucose <6 mmol/l. Intensive treatment reduced the risk of microvascular complications but not macrovascular disease. Of the 4209 participants, 1704 were overweight; 411 were randomised to conventional treatment, 342 were randomised to intensive treatment with metformin and 951 to intensive control.¹¹⁷ Participants treated with metformin had significant reductions in risk of any diabetes-related endpoint (32%, 95% CI 13–47, $p=0.002$) compared to conventional therapy and lower all cause mortality ($p=0.021$) and risk of stroke ($p=0.032$) compared to those treated with other glucose lowering drugs.

More recently, three randomised trials^{118–120} compared intensive glucose control (target HbA1c of $<6\%$ (42 mmol/mol) or 6.5% (48 mmol/mol)) with less intensive control and included a greater number of people with a history of cardiovascular disease. Approximately 40% of participants in the Veterans Affairs Diabetes Trial (VADT)¹²⁰ and 35% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial had pre-existing cardiovascular disease, but the number of people with stroke was not reported. In the Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation (ADVANCE) trial, 9% of participants had a history of stroke. None of the trials demonstrated a reduction in the rate of major cardiovascular events with intensive treatment. A prespecified subgroup analysis of data from the ACCORD study suggested that people with no history of cardiovascular disease, or with baseline HbA1c $\leq 8\%$ had fewer fatal or non-fatal cardiovascular events with intensive therapy. An increase in mortality in the intensive control arm led to the premature cessation of the ACCORD study.

A meta-analysis of seven trials of intensive glucose control versus conventional glucose control found that intensive glucose control led to a reduction in major cardiovascular events of 10% (RR 0.90, 95% CI 0.85–0.96, $p<0.001$).¹²¹ There was no effect on risk of stroke and hypoglycaemia was increased. Subgroup analysis demonstrated that people with shorter duration of diabetes, a longer duration of follow up and lower baseline HbA1c level had a greater benefit from intensive treatment. A further meta-analysis showed a 'U' shaped association between HbA1c level and mortality, with a HbA1c of 7.5% being associated with the lowest HR for all-cause mortality.¹²²

Supporting information to the expert consensus statement

There is insufficient evidence to support a recommendation concerning intensive glucose control to prevent recurrent stroke in people with previous history of ischaemic stroke or TIA. However, many people with stroke will have a new or recent diagnosis of diabetes mellitus and all people with diabetes mellitus are at increased risk of microvascular and macrovascular complications. People with ischaemic stroke or TIA and diabetes mellitus should, like all people with diabetes mellitus, have their glucose control assessed and their treatment reviewed in accordance with relevant guidelines for the treatment of diabetes. The panel voted by 12/12 members for the following consensus statement (Supplemental Table 2).

Evidence-based recommendation

–

Quality of evidence: –

Strength of recommendation: –

Expert consensus statement

In people with ischaemic stroke or TIA and diabetes mellitus, we support aiming for an HbA1c level of <53 mmol/mol (7%, 154 mg/dl) to reduce risk of microvascular and macrovascular complications. However, this target may need to be individualised based on duration of diabetes, age and comorbidities.

In adult people with ischaemic stroke or TIA there is continued uncertainty over the role of intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control.

PICO Question 13: In people with ischaemic stroke or TIA, does use of pioglitazone compared to no pioglitazone reduce the risk of recurrent stroke?

Analysis of current evidence

Pioglitazone is an oral drug from the thiazolidinedione class of peroxisome proliferator-activated receptor γ (PPAR- γ) agonists. It is an insulin sensitising drug and has been shown to reduce the risk of cardiovascular events in people with type 2 diabetes mellitus.¹²³ Clinical trials of the effect of pioglitazone on cardiovascular events in people with stroke and insulin resistance have also been performed.

Our systematic literature search identified 1286 titles and 138 full texts were screened. For this specific PICO question, we identified three randomised controlled trials^{124–126} including 2488 people with ischaemic stroke or TIA treated with pioglitazone and 2492 people with ischaemic stroke or TIA treated with control. One study included people with ischaemic stroke or high-risk TIA and insulin resistance,¹²⁵ one study included people with ischaemic stroke or TIA and insulin resistance or newly diagnosed type 2 diabetes mellitus,¹²⁶ and one study included people

with type 2 diabetes mellitus and macrovascular disease¹²³ with specific reporting of outcomes for people with previous stroke.¹²⁴ One additional study included people with hypertension or dyslipidaemia who had either silent cerebral infarcts or carotid arterial disease (the effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke, PROFIT-J trial).¹²⁷ This was not included in our analysis due to the lack of a symptomatic event, but findings were broadly in keeping with those of the included studies.

Three studies reported the outcome of any stroke and death^{124–126}, two reported the outcome of ischaemic stroke,^{125,126} haemorrhagic stroke,^{125,126} major cardiac events,^{124,125} one trial reported myocardial infarction.¹²⁵ No trials reported data for the outcomes of cardiovascular death, dementia, intracranial bleeding, major bleeding or functional outcome.

Results for all considered outcomes and GRADE scoring, are available in Table 10. The meta-analysis of three included studies^{124–126} showed a significant reduction in risk of any stroke with pioglitazone (HR 0.70, 95% CI 0.52–0.95, $p=0.021$, Figure 14, Table 10). This finding is similar to that of a previous meta-analysis¹²⁸ and the effect was consistent across all included studies. The level of certainty was rated as moderate. Use of pioglitazone would be expected to lead to 25 fewer cases of stroke per 1000 treated. The meta-analysis of two included studies^{125,126} showed a significant reduction in risk of ischaemic stroke with pioglitazone (HR 0.72, 95% CI 0.57–0.90, $p=0.005$, Table 10). The meta-analysis of two included studies^{125,126} showed no reduction in risk of haemorrhagic stroke with pioglitazone (HR 0.99, 95% CI 0.51–1.95, $p=0.984$, Table 10). The meta-analysis of two included studies^{125,127} showed no significant reduction in rate of myocardial infarction (OR 0.75, 95% CI 0.53–1.06, $p=0.104$). The meta-analysis of three included studies^{124–126} showed no significant reduction in risk of death with pioglitazone (HR 0.93, 95% CI 0.75–1.15, $p=0.486$). The level of certainty was rated as low.

Additional information

Pioglitazone is not widely used for secondary prevention of stroke, despite the result of the Insulin Resistance Intervention After Stroke Trial (IRIS) and other trials. This is largely because of reported side effects. Pioglitazone increases risk of weight gain, bone fracture and heart failure. There are also reports of increased risk of bladder cancer. Fracture is a particular concern in people with stroke.¹²⁹ In the IRIS trial the risk of fracture was increased with pioglitazone (13.6% vs 8.8%, HR 1.53, 95% CI 1.24–1.89).¹³⁰ The majority of these fractures were low energy, such as following fall, and just under 50% were serious requiring surgery or hospitalisation. The risk of serious fractures was increased by 1.6% (4.7% vs 3.1%, HR 1.47, 95% CI 1.03–2.09). For comparison, the absolute risk reduction for MI and stroke in the IRIS trial was 2.8% giving a number needed to treat of 36 to prevent one

stroke or MI. The corresponding number to harm for serious fracture is 62. An increase in fracture was also reported in the PROactive trial.¹³¹ Risk of heart failure was not increased in the IRIS trial¹³² but there was a trend towards an increase in the The prospective pioglitazone clinical trial in macrovascular events (PROactive) trial.¹²⁴ It is therefore possible that risk of heart failure will not be increased in people who have insulin resistance and no diabetes mellitus, provided there are attempts to identify heart failure and oedema, with dose reduction if this is found. The risk of bladder cancer may be increased with long-term cumulative exposure and has been demonstrated in meta-analyses of both clinical trials ($n=9114$ participants, OR 1.84, 95% CI 0.99–3.42) and observational studies ($n=4,846,088$, OR 1.13, 95% CI 1.03–1.25).¹³³ The dose of pioglitazone used in trials was typically 45 mg daily, but trial protocols allowed lower doses to be used in the event of side effects. It is unclear whether use of lower doses will be effective and cause fewer side effects. Due to the concerns regarding side effects, pioglitazone should only be used after careful consideration of risk of fracture, bladder cancer and heart failure and counselling of the person. It is also important to note that in the IRIS trial, people with TIA were only included if they had motor weakness and aphasia and this should be considered when using pioglitazone in people with insulin resistance and no diabetes mellitus who have has a TIA. Overall, we rated the quality of evidence as moderate.

Evidence-based recommendation

In people with ischaemic stroke or TIA, who have insulin resistance or type 2 diabetes mellitus, we suggest pioglitazone be used to reduce risk of recurrent stroke.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Weak for intervention** ↑?

Discussion

This guideline document was developed following the GRADE methodology and aims to assist physicians in decision-making regarding pharmacological interventions for the secondary prevention of recurrent stroke after ischaemic stroke or TIA. All recommendations and Expert consensus statements are summarised in Table 11.

Wherever possible, recommendations are provided on the basis of a meta-analysis of randomised controlled trials in defined populations with ischaemic stroke or TIA or from subgroups of these participants. However, such evidence was not always available but there were often studies in primary prevention or in people with other cardiovascular indications. In this context, expert consensus statements were formulated and agreed by the MWG. The principal outcome for each PICO question was the occurrence of recurrent stroke rather than all cardiovascular events. However, other outcomes were rated as critical so were also considered when formulating our recommendations.

Table 10. GRADE evidence profile for PICO question 13: In people with ischaemic stroke or TIA, does use of pioglitazone compared to no pioglitazone reduce the risk of any recurrent stroke?

Certainty assessment				No. of participants		Effect		Certainty	Importance			
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Placebo	Relative (95% CI)	Absolute (95% CI)			
Any stroke												
3	Randomised trials	Serious ^a	Not serious	Not serious	Not serious	None	158/2488 (6.4%)	212/2492 (8.5%)	HR 0.70 (0.52–0.95)	25 fewer per 1000 (from 40 fewer to 4 fewer)	⊕⊕⊕○ Moderate	Critical
Ischaemic stroke												
2	Randomised trials	Very serious ^b	Not serious	Not serious	Not serious	None	126/2002 (6.3%)	175/1994 (8.8%)	HR 0.72 (0.57–0.96)	24 fewer per 1000 (from 37 fewer to 8 fewer)	⊕⊕○○ Low	Critical
Haemorrhagic stroke												
2	Randomised trials	Very serious ^b	Not serious	Not serious	Very serious ^c	None	17/2002 (0.8%)	17/1994 (0.9%)	OR 0.99 (0.51–1.95)	0 fewer per 1000 (from 4 fewer to 8 more)	⊕○○○ Very low	Critical
Major adverse cardiovascular events												
2	Randomised trials	Serious ^d	Not serious	Not serious	Not serious	None	269/2425 (11.1%)	337/2435 (13.8%)	HR 0.78 (0.65–0.95)	28 fewer per 1000 (from 47 fewer to 7 fewer)	⊕⊕⊕○ Moderate	Critical
Myocardial infarction												
2	Randomised trials	Serious ^b	Not serious	Serious ^e	Serious ^f	None	5/234 (2.1%)	4/247 (1.6%)	OR 0.75 (0.53–1.06)	4 fewer per 1000 (from 7 fewer to 1 more)	⊕○○○ Very low	Critical
Death												
3	Randomised trials	Serious ^a	Not serious ^f	Not serious	Serious ^f	None	183/2488 (7.4%)	197/2492 (7.9%)	OR 0.93 (0.75–1.15)	5 fewer per 1000 (from 18 fewer to 10 more)	⊕⊕○○ Low	Critical

CI: confidence interval; HR: hazard ratio; OR: odds ratio.

^aTwo out of three studies at risk of bias but largest study at low risk of bias.^bOne study at high risk of bias.^cVery small sample size.^dOne study at uncertain risk of bias.^eOne of two studies not exclusively a stroke population.^fConfidence intervals crossover 1.00. There were no data for the outcomes cardiovascular death, major bleeding, intracranial bleeding, dementia and functional outcome.

Table 11. Synoptic table of all recommendations and expert consensus statements.

Recommendation	Expert consensus statement
PICO question 1 In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of any recurrent stroke? In people with previous ischaemic stroke or TIA, we recommend blood pressure lowering treatment to reduce the risk of recurrent stroke. Quality of evidence: High ⊕⊕⊕⊕ Strength of recommendation: Strong for intervention ↑↑	
PICO question 2 In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does use of out of office blood pressure measurements compared to outpatient clinic measurements provide better long-term control of blood pressure?	In people with previous ischaemic stroke or TIA, we support the use of out of office blood pressure measurements wherever feasible, to achieve better long-term control of blood pressure
PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. BP < 130/80) versus less intensive (< 140/90 mmHg) target reduce the risk of recurrent stroke? In people with previous ischaemic stroke or TIA, we suggest aiming for a blood pressure target of < 130/80 mmHg to reduce the risk of recurrent stroke. Quality of evidence: Moderate ⊕⊕⊕⊕ Strength of recommendation: Weak for intervention ↑?	
PICO question 4: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does initiation of two blood pressure lowering medications compared to monotherapy reduce the risk of recurrent stroke?	In people with ischaemic stroke or TIA, we support initiation of a combination of two blood pressure lowering drugs to reduce the risk of recurrent stroke, with consideration of monotherapy where there are potential risks of hypotension, such as in frail, elderly people and people with borderline hypertension
PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke? In people with previous ischaemic stroke or TIA we recommend use of a HMGCoA reductase inhibitor to reduce the risk of recurrent ischaemic stroke. Quality of evidence: High ⊕⊕⊕⊕ Strength of recommendation: Strong for intervention ↑↑	
PICO question 6: In people with ischaemic stroke or TIA does working to an intensive cholesterol treatment target, compared to a less intensive target, reduce the risk of any stroke? In people with ischaemic stroke or TIA, we recommend aiming for an LDL cholesterol level of < 1.8 mmol/l (70 mg/dl) to reduce the risk of major cardiovascular events Quality of evidence: Moderate ⊕⊕⊕⊕ Strength of recommendation: Strong for intervention ↑↑	
PICO question 7: In people with a previous ischaemic stroke or TIA who do not achieve recommended LDL-C targets despite taking a maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or a PCSK9-inhibitor superior to an HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke?	

(Continued)

Table 11. (Continued)

Recommendation	Expert consensus statement
	In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, we support the addition of ezetimibe as an option to reduce the risk of recurrent major cardiovascular events
PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet treatment reduce the risk of recurrent stroke?	
In people with previous ischaemic stroke or TIA, we recommend long-term use of antiplatelet therapy to reduce the risk of recurrent stroke. Quality of evidence: Moderate ⊕⊕⊕ Strength of recommendation: Strong for intervention ↑↑	
PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke?	
In people with previous ischaemic stroke or TIA, we recommend against use of dual antiplatelet therapy with aspirin and clopidogrel in the long-term and recommend use of single antiplatelet to reduce the risk of recurrent stroke. Quality of evidence: Very Low ⊕ Strength of recommendation: Weak against intervention ↓?	
PICO question 10: In people with ischaemic stroke or TIA and atherosclerosis, with no other indication for anticoagulation, does antiplatelet therapy combined with a low-dose direct oral anticoagulant compared to antiplatelet therapy alone reduce the risk of recurrent stroke?	
	The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant (rivaroxaban) can be considered to optimise treatment of coronary artery disease or peripheral arterial disease in people with a history of ischaemic stroke or TIA more than 1 month previously. It should not be considered in people with ischaemic stroke or TIA who do not have coronary artery disease or peripheral arterial disease
PICO question 11: In people with an embolic stroke of undetermined source (ESUS) does treatment with a direct oral anticoagulant drug compared to an antiplatelet reduce the risk of recurrent stroke?	
In people with an embolic stroke of undetermined source, we suggest use of antiplatelet therapy and not a DOAC to reduce the risk of recurrent stroke. Quality of evidence: Low ⊕⊕ Strength of recommendation: Weak against intervention ↓?	
PICO question 12: In people with diabetes mellitus and ischaemic stroke or TIA, does intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control reduce the risk of recurrent stroke?	
	In people with ischaemic stroke or TIA and diabetes mellitus, we support aiming for an HbA1c level of <53 mmol/mol (7%, 154 mg/dl) to reduce risk of microvascular and macrovascular complications. However, this target may need to be individualised based on duration of diabetes, age and comorbidities.
PICO question 13: In people with ischaemic stroke or TIA, does use of pioglitazone compared to no pioglitazone reduce the risk of recurrent stroke?	
In people with ischaemic stroke or TIA, who have insulin resistance or type 2 diabetes mellitus, we suggest pioglitazone be used to reduce risk of recurrent stroke. Quality of evidence: Moderate ⊕⊕⊕ Strength of recommendation: Weak for intervention ↑?	




Figure 14. Forest plot for the risk of any stroke in trials comparing treatment with pioglitazone versus placebo in people with TIA or stroke and diabetes or impaired glucose tolerance. Heterogeneity: $I^2 = 19.462$; $Q = 2.483$.

Broadly, the recommendations for interventions for blood pressure lowering or lipid lowering supported a principle of intensive treatment to rigorous targets. In the case of blood pressure reduction, this was applicable for all people except in specific groups who may be at an increased risk of hypotension. Our guideline also covered use of combination antihypertensive treatment, out of office monitoring of blood pressure and addition of novel lipid lowering therapies (ezetimibe or PCSK9 inhibitors). However, while these approaches may be beneficial in many people after stroke, specific evidence in the setting of secondary prevention was often lacking and differences in specific subgroups of stroke remain unknown. Developing this evidence should be a key area of future research. This guideline has not specifically considered use of fibrates, niacin or bempedoic acid therapy either as an add on or in addition to statin therapy. With regard to treatment targets in diabetes mellitus, there was very limited evidence for optimal HbA1c targets after stroke, and limited evidence for the use of specific drugs. Indeed, although we support current primary prevention guidance to optimise control of HbA1c to prevent microvascular targets, the evidence for prevention of macrovascular outcomes remains particularly uncertain and should become a key focus of future research. It would also be important to clarify whether the reduction in stroke seen with GLP1 receptor antagonists in people with diabetes are seen in the secondary prevention setting.

There have been a large number of recent studies exploring antithrombotic strategies. Although antiplatelet therapy has long been established for the secondary prevention of ischaemic stroke, evidence for antiplatelet monotherapy compared to placebo is heavily based upon older trials which used aspirin. We did not specifically address the choice of antiplatelet but given the limited differences in direct comparisons between aspirin and other antiplatelets,²²

we believe that there is likely equivalent benefit from other antiplatelets such as clopidogrel. Although recent studies have suggested much of the benefit occurs early after initiation of treatment,¹³⁴ in the absence of trials excluding potential harms of stopping antiplatelets, long-term antiplatelet monotherapy is indicated. Long-term dual antiplatelet treatment with aspirin and clopidogrel carries an increased risk of harm so we do not recommend this regimen. There are numerous ongoing trials in this area so it is likely that recommendations will be required to be updated in time.

The validity of the recommendations and consensus statements in this guidance results from the systematic approach, GRADE methodology and for many interventions, the availability of high quality randomised controlled trials. However, there are limitations. Firstly, this guideline was specifically restricted to the long-term prevention of recurrent stroke, and therefore does not apply to decisions in the acute phase of stroke. Secondly, it only applies to pharmacological risk factor management after ischaemic events as aetiology-specific interventions are covered in separate guidelines, whilst lifestyle factors will be a focus of future guidance. We recognise that in the coming years treatment is likely to become more specific for the underlying aetiology and that these guidelines may need to be refined. Thirdly, for many of our PICO questions, there remains limited data in specific populations with previous ischaemic stroke or TIA in whom further research is strongly advocated – particularly to better define the role of novel antithrombotic strategies, choice of blood pressure lowering drugs, add on therapy to achieve lipid targets and the role of new treatments for type 2 diabetes mellitus. Finally, we recognise that female participants are often under-represented in clinical trials. We did not specifically address this in our evidence appraisal as this has been covered in a recent ESO guideline.

Plain language summary

This guideline is provided for doctors and other clinicians to help them to decide which medications should be given to most people after an ischaemic stroke or mini-stroke to reduce the risk of future strokes or related problems, such as heart attacks.

Having searched extensively for research published on each of the key questions identified, the most important recommendations we have made, based on available evidence, are:

1. People who have had an ischaemic stroke or transient ischaemic attack should be prescribed medication to lower their blood pressure, if this is raised.
2. Treatment should aim to achieve a blood pressure level below 130/80 mmHg except in some people at an increased risk of problems, such as the very elderly, people with kidney problems and those with severe narrowing of the large blood vessels to the brain.
3. People who have had an ischaemic stroke or transient ischaemic attack should be prescribed HMGCoA reductase inhibitors (statins) to lower their cholesterol.
4. Lipid lowering treatments should aim to keep the low-density cholesterol (bad cholesterol) level below 1.8 mmol/l (70 mg/dl)
5. In the longer term, people who have had an ischaemic stroke or transient ischaemic attack, who do not have a specific reason to have a stronger anticoagulant blood thinner, should be prescribed antiplatelet, but only one such medication at a time.
6. In people with diabetes, or early evidence of it, the anti-diabetic medicine pioglitazone reduces the risk of recurrent stroke, but this should be balanced against an increased risk of broken bones, heart failure and bladder cancer.

Also, where there was insufficient published research to specifically address the question posed, the majority of the working group agreed that:

1. Monitoring blood pressure at home is likely to improve blood pressure control.
2. When treating blood pressure starting treatment with more than one drug is likely to be beneficial for most people.
3. In people whose cholesterol level is not controlled with HMGCoA reductase inhibitors (statins), addition of further drugs should be considered.
4. In some people with narrowing of blood vessels in the heart or the peripheral arteries, the addition of a low-dose anticoagulant blood thinner (a 'DOAC') to an antiplatelet may be considered but this should not be done to treat their stroke.

5. Control of blood sugar to an HbA1c level of <53 mmol/mol (7%, 154 mg/dl) in people with diabetes mellitus and ischaemic stroke or transient ischaemic attack is likely to be beneficial in reducing the risk of cardiovascular events and other complications of diabetes.

Acknowledgements

The authors would like to thank Yvonne Brüchert for her guidance and organisation throughout writing of the guideline, Anna Noel-Storr and Josh Cheyne for their advice on refining our search strategy.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors have completed a declaration of competing interests and details are available in Supplemental Table 1.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for the development of these guidelines was provided by the European Stroke Organisation, Basel, Switzerland. The authors did not receive financial support for the development, writing and/or publication of this guideline.

Ethical approval

Ethical approval was not necessary for the work described in this paper.

Informed consent

Not applicable.

Guarantor

The guarantors of the content of this guideline are Prof Jesse Dawson and Prof Alastair Webb, co-chairs of the Module Working Group.

Contributorship

All members of the MWG were responsible for drafting individual PICO questions. JD and AW wrote the first draft of the manuscript. MTR conducted the statistical analyses. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

ORCID iDs

Jesse Dawson  <https://orcid.org/0000-0001-7532-2475>

Louisa M Christensen  <https://orcid.org/0000-0003-1448-5646>

Gian Marco De Marchis  <https://orcid.org/0000-0002-0342-9780>

Linxin Li  <https://orcid.org/0000-0002-3636-8355>

Cristina Tiu  <https://orcid.org/0000-0001-8532-6218>

Alastair Webb  <https://orcid.org/0000-0002-0630-8204>

Supplemental material

Supplemental material for this article is available online.

References

1. Béjot Y, Bailly H, Durier J, et al. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Med* 2016; 45: e391–e398.
2. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* 2005; 366: 1773–1783.
3. Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *Lancet Neurol* 2015; 14: 903–913.
4. Amarenco P, Lavallée PC, Labreuche J, et al. One-year risk of stroke after transient ischemic attack or minor stroke. *N Engl J Med* 2016; 374: 1533–1542.
5. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010; 376: 112–123.
6. Heuschmann PU, Kircher J, Nowe T, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. *Eur J Prev Cardiol* 2015; 22: 1354–1362.
7. Norrving B, Barrick J, Davalos A, et al. Action plan for stroke in Europe 2018–2030. *Eur Stroke J* 2018; 3: 309–336.
8. Dawson J, Merwick Á, Webb A, et al. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. *Eur Stroke J* 2021; 6: VI.
9. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. *Eur Stroke J* 2019; 4: 198–223.
10. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. *Int J Stroke* 2014; 9: 840–855.
11. Fonseca AC, Merwick Á, Dennis M, et al. European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. *Eur Stroke J* 2021; 6: Clxiii–clxxvi.
12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924–926.
13. Steiner T, Dichgans M, Norrving B, et al. European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines. *Eur Stroke J* 2021; 6: Cxxii–cxxxiv.
14. Thomas J, McDonald S, Noel-Storr A, et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. *J Clin Epidemiol* 2021; 133: 140–151.
15. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: d5928.
16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; 366: 14898.
17. Harrison JK, Reid J, Quinn TJ, et al. Using quality assessment tools to critically appraise ageing research: a guide for clinicians. *Age Ageing* 2017; 46: 359–365.
18. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* 2011; 64: 380–382.
19. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; 360: 1903–1913.
20. Kaplan RC, Tirschwell DL, Longstreth WT Jr, et al. Blood pressure level and outcomes in adults aged 65 and older with prior ischemic stroke. *J Am Geriatr Soc* 2006; 54: 1309–1316.
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 358: 1033–1041.
22. Yusuf S, Sleight P, Pogue J, et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342: 145–153.
23. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med* 2008; 359: 1225–1237.
24. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. *JAMA* 1974; 229: 409–418.
25. PATS, Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. *Chin Med J* 1995; 108: 710–717.
26. Gayet JL. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003; 21: 1771.
27. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non-disabling ischemic stroke. *Stroke* 1993; 24: 543–548.
28. Eriksson S, Olofsson B and Wester P. Atenolol in secondary prevention after stroke. *Cerebrovasc Dis* 1995; 5: 21–25.
29. Liu L, Zhang Y, Liu G, et al. The felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens* 2005; 23: 2157–2172.
30. Martí Massó JF and Lozano R. Nicardipine in the prevention of cerebral infarction. *Clin Ther* 1990; 12: 344–351.
31. Zonneveld TP, Richard E, Vergouwen MD, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. *Cochrane Database Syst Rev* 2018; 7: CD007858.
32. Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. *Hypertension* 2017; 69: 171–179.
33. Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention

- of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet* 2021; 397: 1625–1636.
34. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. *JAMA* 2014; 312: 799–808.
 35. Kerry SM, Markus HS, Khong TK, et al. Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: a community-based randomized controlled trial. *Can Med Assoc J* 2013; 185: 23–31.
 36. Davison WJ, Myint PK, Clark AB, et al. Does self-monitoring and self-management of blood pressure after stroke or transient ischemic attack improve control? TEST-BP, a randomized controlled trial. *Am Heart J* 2018; 203: 105–108.
 37. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021; 42: 3227–3337.
 38. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. *PLoS Med* 2017; 14: e1002389.
 39. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet* 2013; 382: 507–515.
 40. Mant J, McManus RJ, Roalfe A, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention after Stroke—Blood pressure) randomised controlled trial. *BMJ* 2016; 352: i708.
 41. Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. *JAMA Neurol* 2019; 76: 1309–1318.
 42. Park JM, Kim BJ, Kwon SU, et al. Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis: a result of randomized trial. *J Hypertens* 2018; 36: 1936–1941.
 43. Rothwell PM, Howard SC and Spence JD; Carotid Endarterectomy Trialists Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. *Stroke* 2003; 34: 2583–2590.
 44. Béjot Y, Duloquin G, Graber M, et al. Current characteristics and early functional outcome of older stroke patients: a population-based study (Dijon Stroke Registry). *Age Ageing* 2021; 50: 898–905.
 45. Yan J, Zheng K, Liu A, et al. The impact of cognitive function on the effectiveness and safety of intensive blood pressure control for patients with hypertension: a post-hoc analysis of SPRINT. *Front Cardiovasc Med* 2021; 8: 777250.
 46. Graber M, Garnier L, Mohr S, et al. Influence of pre-existing mild cognitive impairment and dementia on post-stroke mortality. The Dijon Stroke Registry. *Neuroepidemiology* 2020; 54: 490–497.
 47. Pendlebury ST and Rothwell PM; Oxford Vascular Source. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. *Lancet Neurol* 2019; 18: 248–258.
 48. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008; 358: 1887–1898.
 49. Peralta CA, McClure LA, Scherzer R, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of small subcortical strokes (SPS3) randomized trial. *Circulation* 2016; 133: 584–591.
 50. Beddhu S, Rocco MV, Toto R, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. *Ann Intern Med* 2017; 167: 375–383.
 51. MacDonald TM, Williams B, Webb DJ, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. *J Am Heart Assoc* 2017; 6: e006986.
 52. Brown MJ, McInnes GT, Papst CC, et al. Amlodipine and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. *Lancet* 2011; 377: 312–320.
 53. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med* 2009; 122: 290–300.
 54. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension* 2012; 59: 1124–1131.
 55. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. *J Hypertens* 2010; 28: 1584–1590.
 56. Conn VS, Ruppert TM, Chase JA, et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. *Curr Hypertens Rep* 2015; 17: 94.
 57. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018; 39: 3021–3104.
 58. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. *J Am Coll Cardiol* 2014; 64: 2071–2082.
 59. Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet* 2010; 375: 906–915.
 60. Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; 338: b1665.
 61. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. *Circulation* 2011; 123: 1611–1621.
 62. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med* 2008; 359: 2417–2428.
 63. Ogihara T, Saruta T, Rakugi H, et al. Combination therapy of hypertension in the elderly: a subgroup analysis of the

- combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertens Res* 2015; 38: 89–96.
64. Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens* 2011; 29: 1649–1659.
 65. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004; 363: 757–767.
 66. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006; 355: 549–559.
 67. Hosomi N, Nagai Y, Kohriyama T, et al. The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. *EBioMedicine* 2015; 2: 1071–1078.
 68. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. *Circulation* 1999; 99: 216–223.
 69. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. *N Engl J Med* 2000; 343: 317–326.
 70. Vergouwen MD, de Haan RJ, Vermeulen M, et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. *Stroke* 2008; 39: 497–502.
 71. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. *Stroke* 2007; 38: 3198–3204.
 72. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. *N Engl J Med* 2020; 382: 9–19.
 73. Hosomi N, Kitagawa K, Nagai Y, et al. Desirable Low-density lipoprotein cholesterol levels for preventing stroke recurrence: a post hoc analysis of the J-STARS study (Japan statin treatment against recurrent stroke). *Stroke* 2018; 49: 865–871.
 74. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018; 379: 2097–2107.
 75. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015; 372: 2387–2397.
 76. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017; 376: 1713–1722.
 77. Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved reduction of outcomes: vytorin Efficacy International Trial). *Circulation* 2017; 136: 2440–2450.
 78. Jukema JW, Zijlstra LE, Bhatt DL, et al. Effect of alirocumab on stroke in ODYSSEY OUTCOMES. *Circulation* 2019; 140: 2054–2062.
 79. Giugliano RP, Pedersen TR, Saver JL, et al. Stroke Prevention with the PCSK9 (Proprotein convertase subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. *Stroke* 2020; 51: 1546–1554.
 80. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *Lancet* 2010; 376: 1670–1681.
 81. Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380: 581–590.
 82. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia (AITIA study). *Thromb Haemost* 1979; 41: 135–141.
 83. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med* 1978; 299: 53–59.
 84. Bousser MG, Eschwege E, Haguénau M, et al. “Aicla” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. *Stroke* 1983; 14: 5–14.
 85. Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. *Stroke* 1983; 14: 15–22.
 86. A Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. *Stroke* 1987; 18: 325–334.
 87. ESPS Group. European stroke prevention study. *Stroke* 1990; 21: 1122–1130.
 88. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry* 1991; 54: 1044–1054.
 89. The Salt Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. *Lancet* 1991; 338: 1345–1349.
 90. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996; 143: 1–13.
 91. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine Study (CATS) in thromboembolic stroke. *Lancet* 1989; 1: 1215–1220.
 92. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. *J Stroke Cerebrovasc Dis* 2000; 9: 147–157.
 93. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994; 308: 81–106.
 94. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364: 331–337.

95. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006; 354: 1706–1717.
96. Benavente OR, Hart RG, McClure LA, et al.; The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *N Engl J Med* 2012; 367: 817–825.
97. Halkes PH, van Gijn J, Kappelle LJ, et al.; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet* 2006; 367: 1665–1673.
98. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med* 2008; 359: 1238–1251.
99. Greving JP, Diener HC, Reitsma JB, et al. Antiplatelet therapy after noncardioembolic stroke. *Stroke* 2019; 50: 1812–1818.
100. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 2017; 377: 1319–1330.
101. Perera KS, Ng KKH, Nayar S, et al. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS Trial. *JAMA Neurol* 2020; 77: 43–48.
102. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 2018; 391: 219–229.
103. Sharma M, Hart RG, Connolly SJ, et al. Stroke outcomes in the COMPASS trial. *Circulation* 2019; 139: 1134–1145.
104. Galli M, Capodanno D, Benenati S, et al. Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother* Epub ahead of print 19 June 2021. DOI: 10.1093/ehjcvp/pvab043.
105. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J* 2011; 32: 2781–2789.
106. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet* 2009; 374: 29–38.
107. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012; 366: 9–19.
108. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. *N Engl J Med* 2018; 379: 1332–1342.
109. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med* 2020; 382: 1994–2004.
110. Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. *N Engl J Med* 2020; 383: 1735–1745.
111. Hart RG, Sharma M, Mundt H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. *N Engl J Med* 2019; 7: 147–201.
112. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. *N Engl J Med* 2019; 380: 1906–1917.
113. Kamel H, Longstreth WT Jr, Tirschwell DL, et al. The AtRisk cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. *Int J Stroke* 2019; 14: 207–214.
114. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. *Diabetes Care* 1999; 22: 1077–1083.
115. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med* 2008; 168: 2070–2080.
116. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837–853.
117. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998; 352: 854–865.
118. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; 358: 2545–2559.
119. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; 358: 2560–2572.
120. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; 360: 129–139.
121. Zhang CY, Sun AJ, Zhang SN, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Ann Med* 2010; 42: 305–315.
122. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. *Lancet* 2010; 375: 481–489.
123. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. *Lancet* 2005; 366: 1279–1289.
124. Wilcox R, Boussier MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone clinical trial in macroVascular events 04). *Stroke* 2007; 38: 865–873.
125. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med* 2016; 374: 1321–1331.
126. Tanaka R, Yamashiro K, Okuma Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT Study. *J Atheroscler Thromb* 2015; 22: 1305–1316.
127. Yoshii H, Onuma T, Yamazaki T, et al. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. *J Atheroscler Thromb* 2014; 21: 563–573.
128. Lee M, Saver JL, Liao HW, et al. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. *Stroke* 2017; 48: 388–393.

129. Kanis J, Oden A and Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. *Stroke* 2001; 32: 702–706.
130. Viscoli CM, Inzucchi SE, Young LH, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. *J Clin Endocrinol Metab* 2017; 102: 914–922.
131. Dormandy J, Bhattacharya M and van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. *Drug Safety* 2009; 32: 187–202.
132. Young LH, Viscoli CM, Schwartz GG, et al. Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. *Circulation* 2018; 138: 1210–1220.
133. Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. *Cancer Med* 2018; 7: 1070–1080.
134. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. *Lancet* 2016; 388: 365–375.